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ABSTRACT 
 
Lack of evidence for the role of skewed X chromosome inactivation in the female 
predisposition to Sjogren Syndrome 
 
Melda Kantar 
M.S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
August 2008,  Pages 91 
 
Sjogren Syndrome is an autoimmune disease with one of the highest prevalences and 
unknown etiology.  The majority of the patients (~90%) are female similar to several 
other autoimmune diseases.  Based on this observation, a hypothesis was proposed stating 
that X chromosome inactivation (XCI) could be involved in female predisposition to 
autoimmunity.  XCI is a physiological mechanism which takes place early in 
development resulting in the transcriptional silencing of one of the pair of X 
chromosomes at random in each cell.  A significant deviation from a random distribution 
of two cell populations with paternal and maternal X chromosome inactive is called 
skewed XCI.  Skewing in the dendritic cell population involved in tolerance induction in 
the thymus was proposed to cause escape of autoreactive lymphocytes and result in 
autoimmunity (Immunol Today, 19, 352-7, 1998).  Skewed XCI was observed in 
scleroderma (Arth Rheum 52, 1564-70, 2005) and autoimmune thyroiditis (Eur J Hum 
Genet 14, 791-7, 2006).  But this observation is not true for all autoimmune diseases.  For 
example, the XCI profiles of primary biliary cirrhosis patients are similar to normal 
controls (Hepatol Res 37, Suppl 3, 384-8, 2007).  The aim of this study is to determine 
the XCI profiles of patients diagnosed with primary Sjogren Syndrome, manifesting 
exocrinopathy or secondary Sjogren Syndrome displaying additional systemic features.  
DNA was isolated from the peripheric blood samples of 78 Sjogren syndrome patients 
and 160 controls.  XCI profile was determined by the genotyping of a polymorphism in 
the androgen receptor (AR) gene.  For this analysis, restriction enzyme HpaII was used 
which does not cut methylated regions. Analysis was done with Genescan Abi Prism 310 
or 8% polyacrylamide gel electrophoresis and densitometric analysis.  Extreme skewing 
(>90%) of XCI was  observed in 3 (5.9%) patients and 3 controls (2.4%) samples (P = 
0.3651).  Our findings do not support a role for skewed XCI in Sjogren Syndrome.  
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ÖZET 
 
Sjogren sendromu ile X inaktivasyonu bozukluğu arasında bir ilişki bulunmuyor 
 
Melda Kantar 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Tayfun Özçelik 
Ağustos 2007,  Sayfa 91 
 
Sjogren sendromu etiyolojisi bilinmeyen ve prevalansı en yüksek olan otoimmün 
hastalıklardan biridir. Pek çok otoimmün hastalıkta olduğu gibi hastaların büyük bir 
çoğunluğu (~%90) kadındır. Bu gözlemden yola çıkarak, bozuk X inaktivasyonunun 
otoimmun hastalıkları tetikleyebileceği hipotezi ileri sürülmüştür (Immunol Today, 19, 
352-7, 1998). X inaktivasyonu kadınlarda erken gelişme döneminde hücrelerdeki X 
kromozomu çiftinden rastgele birinin susturulmasıyla sonuçlanan normal bir fizyolojik 
olaydır.  Hücrelerin önemli bir kısmında aynı X kromozomunun susturulması bozuk X 
inaktivasyonu olarak adlandırılır.  Timusda, tolerans oluşumunda rol alan dendritik 
hücrelerdeki X inaktivasyonu bozukluğunun otoreaktif lenfositlerin kaçmasına ve 
otoimmüniteye neden olabileceği hipotezi ileri sürülmüştür.  Skleroderma (Arth Rheum 
52, 1564-70, 2005) ve otoimmün tiroiditis (Eur J Hum Genet 14, 791-7, 2006) 
hastalıklarında bozuk X inaktivasyonu gözlenmiştir. Fakat bu gözlem tüm otoimmün 
hastalıklar için geçerli değildir. Örneğin primer biliyer siroz hastalarının X inaktivasyonu 
profilleri normal kontroller gibidir (Hepatol Res 37, Suppl 3, 384-8, 2007). Bu çalışmanın 
amacı sadece salgı bezi patolojisi olan primer Sjogren Sendromu ve aynı zamanda başka 
sistemik patolojiler içeren sekonder Sjogren Sendromu tanısı alan hastalarda X-
inaktivasyonu profillerinin belirlenmesidir. 78 hasta ve 160 kontrolün periferik kanından 
DNA izole edilmiştir. X inaktivasyon profili androjen reseptör geninde bulunan bir 
polimorfizmin genotiplemesi ile belirlenmiştir. Bu inceleme için metilli bölgeleri 
tanımayan bir restriksiyon enzimi olan HpaII ile kesim yapılmış ve hedef bölge 
çoğaltılmıştır. İnceleme Genescan Abi Prism 310 ya da %8 poliakrilamid jel elektroforezi 
ve densitometrik ölçümle yapılmıştır. İleri derecede (>%90) X inaktivasyonu bozukluğu 
3 (%5.9) hasta ve 3 kontrol (%2.4) örneğinde gözlenmiştir (P = 0.3651). Bulgularımız X 
inaktivasyonu bozukluğu ile Sjogren Sendromu arasında bir ilişkinin varlığını 
desteklememiştir. 
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CHAPTER I: INTRODUCTION 
 
1.1. Sjogren Syndrome 
 
Sjogren Syndrome is a chronic and systemic autoimmune disease 
characterized by progressive lymphocytic infiltration of polyglandular tissue and 
subsequent tissue destruction.  This results in the functional impairment of 
salivary and lacrimal glands, and causes keratoconjunctivitis sicca, which refers to 
dryness of the eyes and xerostomia meaning dryness of the mouth.  The ease and 
safety of a minor salivary gland biopsy enables study of the molecular biology of 
this autoimmune exocrinopathy.  With microscopic examination, the lymphocytic 
replacement of the epithelium and lymphoepithelial lesion can be observed.  It is 
an inflammatory rheumatic disease with main features in the eyes and mouth 
(Ramos-Casals, 2005; Kassan, 2004; Schwartz, 2007; Fox, 2000). 
 
1.1.1 History 
 
Sjogren Syndrome is a relatively newly identified disease.  Its histology 
was described and a link with arthritis was reported in the late 19th and early 20th 
centuries as single case reports.  In 1933, Henrick Sjogren reported the association 
of xeropthalmia meaning dry eyes and xerostomia with polyarthritis in 19 cases.  
In the early years, research was mainly on the opthalmology of Sjogren 
Syndrome.  The clinical spectrum of Sjogren Syndrome in 1956 was defined in 62 
subjects.  The rheumatologic aspect of Sjogren Syndrome was heavily 
emphasized when the distinction between primary and secondary Sjogren 
Syndrome was first described in 1965.  In 1970s, autoantibodies characteristic of 
Sjogren Syndrome were described.  In 1990s, the diagnostic tests became a 
routine procedure and research on disease-modifying drugs started (Venables, 
2004).  Table 1.1 shows the timeline of advances in delineating Sjogren 
Syndrome. 
 
1 
Table 1.1 Timeline of important advances in delineating Sjogren Syndrome 
(Venables et al.,2004) 
 
Year  Progress 
1888 Case reports of Hadden and Rowlands 
1892 Case report of Miculicz (histology described) 
1926 Description of three patients by Gougerot 
1928 Case report of Houwer (link with arthritis) 
1933 Description of nineteen patients with keratoconjuctivitis sicca by Sjogren 
1946 Translation of Sjogren thesis to English  
1953 “Sjogren syndrome” established as a term in literature 
1965 Primary and secondary Sjogren Syndrome distinguished 
1970 Anti-Ro (SS-A) and anti-La (SS-B) in Sjogren Syndrome is determined 
1980 Extraglandular symptoms described 
1990 Routine application of diagnostic tests  
1990 Trials of disease-modifying drugs 
2002 Consensus diagnosis criteria 
 
 
 
 
Sjogren Syndrome is a milder disease in comparison to rheumatoid 
arthritis (RA) or systemic lupus erythematosus (SLE).  There was not a strict 
classification criteria for the syndrome until lately.  Its low mortality and 
underdiagnosis prevented the disease from being a primary research area and 
caused Sjogren patients to be underdiognosed and undertreated (Venables, 2004).  
 
 
 
 
 
 
2 
1.1.2 Symptoms 
 
The symptoms in relation to the eyes are more serious than the symptoms 
of the mouth.  Underlying collagen can be revealed as a result of erosions in the 
conjunctiva leading to the appearance of filamentary keratitis.  More dental care is 
a sign of xerostomia.  Parotid swelling occurs in half of the patients.  Other 
exocrine glands can be involved effecting skin, vagina, gastrointestinal tract, 
colon and rectum.  70% of the patients complain of fatigue. 
Systemic features include renal involvement, neurological involvement, 
vascular involvement, cutenous involvement, pulmonary involvement, 
muscuskeletal involvement, gastroenterologic involvement, congenital heart block 
and lymphoma (Venables, 2004; Kassan, 2008; Ramos-Casals, 2005).  
 
1.1.3 Criteria for diagnosis 
 
Until recently, a consensus international diagnosis criteria for Sjogren 
Syndrome was unavailable.  Because of its heterogeneous nature, Sjogren 
Syndrome is hard to diagnose.  It has been hard to achieve a consensus because 
there are diseases that mimic Sjogren Syndrome such as age-related atrophy, 
chronic anxiety, chronic fatigue syndrome, fibromyalgia and dry eyes and mouth 
symptoms (DEMS).  Previously, there were `Copenhagen`, `Californian` and 
`European` criteria.  The revised American-European consensus criteria was 
established in 2002 (Vitali, 2002).  The application of this criteria was essential 
both for clinical diagnosis and research.  
The current criteria is as designated in Table 1.2.  Four of the listed 
observations including either the fourth or sixth one is needed to diagnose a 
patient as Sjogren Syndrome.  The observations include objective signs and 
symptoms of dryness.  Evaluation of symptoms is based on a short questionaire.  
Ocular signs are evaluated based on Schirmer`s test or Rose Bengal staining.  Oral 
signs are evaluated with scintiagraphy, sialography or a test for salivary flow rate.  
One observation that indicates the inflammatory nature of the disease is the 
3 
characteristic appearance of a minor salivary gland biopsy with focal 
inflammation.  Focal lymphocytic infiltrates are expected in the minor salivary 
gland biopsy resulting in a focus score of more than 1 (A cluster of 50 or more 
lymphocytes is called a focus).  Another observation that indicates inflammation 
is the presence of characteristic autoantibodies, rheumatoid factor or anti-nuclear 
antibodies in the serum.  To prevent confusion with dry eyes and mouth 
symptoms (DEMS), these observations for determining the inflammatory nature 
of the disease are necessary (Venables, 2004). 
 
 
Table 1.2 Current Criteria for Sjogren Syndrome diagnosis (Venables et al, 2004) 
 Ocular symptoms 
1. Have you had daily, persistance, troublesome dry eyes for more than 3 months 
2. Do you have a recurrent sensation of sand and gravel in the eyes 
I 
3. Do you use a tear substitutive more than 3 times a day 
 Oral symptoms 
1. Have you had a daily feeling of dry mouth for more than 3 months 
2. Have you had recurrently or persistantly swollen salivary glands as an adult 
II 
3. Do you frequently drink liquids to aid in swallowing dry foods 
III Positive Schirmer`s I test or Rose Bengal score 
IV Abnormal lower lip biopsy (focus score >= 1) 
V Positive result for unstimulated whole salivary flow (<= 1.5ml in 15 min) 
VI Antibodies to Ro (SS-A) or La (SS-B), or both 
 
In diagnosis, it is important to show that the salivary dysfunction roots 
from an inflammation.  Salivary dysfunction can also be caused by drugs, 
infection, head and neck radiation treatment, acquired immune deficiency 
syndrome (AIDS), preexisting lymphoma, sarcoidosis, graft versus host disease 
(GVHD), use of anticholinergic drugs and the autonomic nervous system.  These 
are exclusions to diagnosis (Venables, 2004). 
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 1.1.4 Treatment 
 
Until recently, the treatment was only topical and symptomatic to improve 
moisture; decrease inflammation and prevent damage.  These include performing 
general measures and using tear and saliva substitutes and mucolytic agents.  
Recently, research on disease-modifying drugs have been intensified with the 
recognition that Sjogren Syndrome is a disease of considerable morbidity.  
Currently a more aggressive approach to therapy is applied with  topical and 
systemic treatment.  The disease-modifying drugs include secretagogues and 
immunomodulatory drugs.  
If Sjogren Syndrome is a consequence of the destruction of glands, 
secretagogues can not be a rational form of treatment.  However there is currently 
increasing evidence that hypofunction of the glands is caused by inflammation 
and dryness is caused by this hypofunction.  Sialogogues, pilocarpine and 
cevimeline hydrocholorine are both cholinergic agents with muscarinic agonist 
activity and are of proven benefit for Sjogren Syndrome (Vivino, 2001 ; Fife, 
2002).   
It seems logical to use immunomodulatory drugs because most of the 
morbidity is caused by widespread disruption of the immune system.  There is 
supportive evidence for the use of hydroxycholoroquine sulphate.  These can be 
effective to cure most disabling features such as fatique (Fox, 1996). 
There is limited research on the use of biological agents for the treatment 
of Sjogren Syndrome.  There are trials of a recombinant interferon-alpha, anti-
tumour necrosis factor antibody Infliximab and anti-B cell antibodies such as anti-
CD20 antibody Rituximab (Cummins, 2003; Serge, 2002; Bradley, 2003). 
Anti-inflammatory agents and cytotoxic drugs are used to treat systemic 
complications (Venables, 2004). 
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 1.1.5 Epidemiology 
 
The prevalance of Sjogren Syndrome have been controversial based on the 
lack of a consensus diagnostic criteria (Thomas, 1998).  An estimated 2 to 4 
million people in the United States have this syndrome.  The heterogeneity of its 
clinical manifestations is a barrier against its diagnosis in some cases.  
Approximately 1 million people have an established diagnosis of Sjogren 
Syndrome.  No racial predisposition to the syndrome is known.  Females are 
affected more than males in a 9:1 ratio.  It is a disease of middle-aged or elderly 
women although it can occur at any age.  It has a low pediatric prevelance.  
Approximately 60% of the Sjogren patients have secondary syndromes.  
Secondary Sjogren Syndrome results in death, especially in cases with 
myelopathy (Schwartz, 2007; Kassan, 2004). 
 
1.1.6 Classification as primary and secondary Sjogren Syndrome 
 
The presence of autoimmune inflammatory exocrinopathy and sicca 
symptoms alone is designated as primary Sjogren Syndrome.  The occurence of 
keratoconjuctivitis sicca and xerostomia in association with another connective 
tissues diseases is designated secondary Sjogren Syndrome.  These associated 
autoimmune diseases could be rheumatoid arthritis, systemic lupus 
erythematosus, scleroderma (SSc), muscle connective tissue disease (MCTD), 
subacute cutaneous lupus erythematosus (SCLE), polymyositis, sarcoidosis, 
systemic vasculitides and antiphospholipid syndrome (Ramos-Casals, 2007).  The 
prevelance of Sjogren Syndrome in other autoimmune diseases is shown in       
Table 1.3. 
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 Table 1.3  Prevalence of sicca features and associtated Sjogren Syndrome in 
systemic autoimmune diseases (Ramos-Casals et al, 2007) 
 
Diseases Sicca features (%) Sjogren Syndrome (%)  
Systemic lupus erythematosus 18-34 9-19 
Rheumatoid arthritis 30-50 4-31 
Systemic sclerosis 67-68 14-20 
Sarcoidosis 9 3 
Cryoglobulinemic vasculitis 42 - 
 
Sjogren Syndrome patients have a 44 times increased risk of developing B cell 
lymphoma (Kassan, 1978).  Lymphoma is the cause of death in one of five 
Sjogren patients (Ioannidis, 2002; Bolstad, 2002).  The prevalence of malignant 
lymphoma in Sjogren Syndrome patients is 4.3%, being mostly low-grade 
marginal zone B-cell lymphoma.  Whether this lymphoma is primary or 
secondary to Sjogren Syndrome is unknown. (Yamamoto, 2002). 
 
1.1.7. Pathophysiology and Etiology 
 
The etiology of Sjogren Syndrome is unknown.  It is a complex disease, in 
other words, both genetic predisposition and environmental factors have a role in 
the pathogenesis.  The aetiopathogenesis is probably sequential leading to 
selective dysfunction of target organs caused by migration of lymphocytes 
(Ramos-Casals, 2005).  In a minor salivary biopsy, the infiltrated lymphocytes 
can be observed as in Figure 1.1. 
Sjogren Syndrome is generally accepted a T-cell mediated disease.  The 
infiltrating cells in the glands are mostly T cells.  T helper cells (CD4+) are more 
commonly seen than cytotoxic T cells (CD8+) in a ratio of 5:3.  In labial salivary 
glands of Sjogren Syndrome patients, 2% of the infiltrating mononuclear cells 
were reported to be dendritic cells (Xanthou, 1999).  Additionally, ductal and 
acinar epithelial cells of Sjogren Syndrome patients express B7.1 and B7.2              
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co-stimulatory molecules (Monoussakis, 1999).  The majority of the T cells in the 
glands express CD45RO, which is a feature of activated or memory cells.               
T helper (Th1) cytokines such as interleukin 2 (IL-2), interleukin 10 (IL-10) are 
produced in much higher amounts in comparison to normal controls.  There is 
also an increase in T helper 2 (Th2) cytokines such as interleukin 4 (IL-4) and 
interleukin 5 (IL-5).  There is additionally an increase in cytokines interleukin 1 
(IL-1), interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor (TNF) 
and interferon gamma (IFN-γ) expressed by the tissue (Fox, 1994, Ohyama, 
1996).  A few T cells proliferate in the area.  It is possible that memory T cells are 
semiactivated and the other T cells are probably suppressed in response to the 
strong immune response (Yamamoto, 2003).  
 
 
 
 
 
Figure 1.1 Minor salivary gland biopsy photomicrographs A) 50X, Sjogren 
Syndrome B) 50X, normal C) D) 200X, Sjogren Syndrome E) F) 500X, Sjogren 
Syndrome (Fox et al., 2000) 
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 It seems likely that Sjogren Syndrome results from glandular destruction 
so infiltrating cytotoxic T cells are candidates for the pathogenesis.  Both 
apoptosis with perforin/granzyme B and Fas/Fas ligand pathways were implicated 
with the etiology.  It was shown that cytotoxic T cells expressing integrin localize 
around acinar epithelial cells that express E-cadherin (Fujihare, 1999).  However 
the findings in relation to glandular apoptosis in Sjogren Syndrome patients in 
comparison to controls is controversial (Ohlson, 2001;Yammato 2003). 
Several features of the disease can result from B cell stimulation and 
hyperglobulinemia.  20% of the infiltrating population consists of B cells.  
Antigen-driven, germinal center-type B cell response takes place within the 
salivary glands of Sjogren syndrome patients.  Immunoglobulin G (IgG) isotype is 
extraordinarily seen more than immunoglobulin A (IgA) in the glands and in the 
serum.  Immunoglobulin variable λ (IgVλ) light chain usage in primary Sjogren 
Syndrome was researched and it was found that there were differences in V-J 
recombination in Sjogren Syndrome patients from controls.  It was concluded that 
there are defects in B-cell selection and maturation; immunoglobulin receptor 
editing and mutational targetting.  There is B cell clonal expansion with antigen 
stimulation (Scott, 1998;Yammato, 2003). 
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Figure 1.2   Steps of the Sjogren Syndrome pathogenesis according to epithelithis 
model (Ramos-Casals et al, 2005) 
 
The current aetiopathogenic hypothesis of Sjogren Syndrome is 
autoimmune epithelitis.  According to this theory, intrinsic influences such as 
genetic make-up and/or extrinsic influences such as environmental factors form 
the background for the pathogenesis.  The initiation occurs as a result of an 
altered immune system incapable of discriminating between ‘foreign’, ‘self’ 
molecules and /or altered self antigens of the gland epithelium.  This results in 
autoimmunity.  The establishment process includes an abnormal immune response 
with abnormal T cell dysfunction and B cell hyperreactivity.  This results in 
lymphocytic destruction forming histopathological lesions of acinar and ductal 
epithelial cells.  It may also cause change in cytokine and chemokine secretion 
leading to perpetuation of the response.  Then mechanisms of tissue damage such 
as apoptosis are activated leading to chronic inflammation with fibroses and loss 
of secretory function.  Other mechanisms involved can be enhanced proteolytic 
mechanisms or altered epithelial repair.  Apoptosis is thought to be related to 
formation of further abnormal autoantigens (Ramos-Casals, 2005).  An overview 
of this model is given in Figure 1.2. 
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There are several potential mechanisms that are related to the etiology of 
Sjogren Syndrome: (1) Unsuccessful deletion of autoimmune T cells in the 
thymus.  (2) Expression of increased levels of cell adhesive molecules in high 
endothelial venules leads to homing of autoimmune lymphocytes to glands.  (3) 
Increase in expression of human leukocyte antigens (HLAs) in aiding increased 
presentation of antigens to lymphocytes.  (4) In the gland, lymphocyte activation 
by their interaction with HLA-DR, cell adhesion molecules, and co-stimulatory 
factors.  (5) Circulating autoantibodies against the ribonucleoproteins Ro and La  
(6) Inflamatory response is perpetuated by the secretion of pro-inflammatory 
cytokines by lymphocytes and epithelial cells.  (7)  Anti-apoptotic markers such 
as Bcl-2 and Bcl-x in the lymphocytes and apoptotic markers such as Fas and Bax 
in the epithelium are upregulated (Fox, 2000). 
The role of apoptosis in autoimmune diseases including Sjogren 
Syndrome has been a major research area.  Apoptosis has been proposed to have 
two aspects in the Sjogren Syndrome pathogenesis:  (1) Increase in apoptosis in 
the ductal epithelial cells of the salivary glands was suggested to cause salivary 
decrease.  (2) Accumulation of lymphocytes and displacement of functional 
acinar cells result from lymphocytes escaping apoptosis because of the defects of 
in the pathway.  
Another major hypothesis on the etiology of Sjogren Syndrome is 
autonomic dysfunction.  It was seen that half of the acinar cells remain 
histologically intact when patient biopsies were observed.  So hypofunction rather 
than destruction of glandular epithelial cells is proposed as a theory for the 
secretory problem in Sjogren Syndrome.  In one model, the gland can not receive 
enough neural signals from medulla.  This can result from decreased neural 
innervation.  Decreased neural axon-specific protein 9.5 and synaptophysin was 
observed with immunohistology (Konttinen, 1992).  Release of acetylcholine is 
needed for glandular secretion.  Cytokines can be toxic to the nerves and prevent 
the release of acetylcholine.  It was shown in vitro and in transgenic mice that 
interleukin 1 and tumor necrosis factor α are toxic to nerves (Main, 1993).  
Another model suggests that acinar cells respond in a limited manner to neural 
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input, in other words there are problems in post signal transduction.  Decrease of 
protein kinase C (PKC) isoforms involved in secretory response were reported for 
epithelial and myoepithelial cells (Törnwall 1997; Campbell, 1995).  Antibodies 
against muscarinic M3 receptors were also found in Sjogren Syndrome patients 
(Borda, 1996; Venables, 2004; Fox, 2000). 
Interactions of ductal and acinar cells with matrix may be important in the 
etiology of the disease.  These interactions mediate response to cytokines, growth 
signals and hormones; they aid in homeostasis, regeneration and function of the 
cells.  It was reported that the receptors on epithelial cells and some cytokines are 
expressed at higher amounts in these patients (Fox, 1994, Ohyama, 1996).  It was 
also reported that cell-matrix interactions are important for secretory functions of 
to glandular cells in response muscarinic M3 agonists (Laurie, 1996).   
The higher prevalence of Sjogren Syndrome in perimenopausal women 
suggest that hormonal factors can have a role in the disease etiology.  The 
research on this field is controversial (Ramos-Casals, 2005). 
 
 
1.1.7.1 Genetic predisposition 
 
Based on animal models, familial aggregation and candidate gene 
association studies, a genetic predisposition to Sjogren Syndrome was suggested.  
Several families with more than two cases of Sjogren Syndrome have been 
identified and presence of multiple autoimmune diseases in families and in an 
individual have frequently been reported (Lichtenfeld, 1976; Koivukangas, 1973; 
Mason, 1971; Boiling, 1983, Sabio, 1983; Tanaka, 2001).  Approximately 35% of 
Sjogren Syndrome patients have relatives with other autoimmune diseases. 
Limited number of case reports is present on twin concordance of primary 
Sjogren Syndrome.  Reported twins have very similar phenotypes including 
clinical presentation, serological data, specificity of immune response to Ro/SSA 
and biopsy focus score (Scofield, 1997; Besena, 1991; Kogo, 1980; Bolstad, 
2000; Bolstad, 2002). 
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1.1.7.2. Associated genes 
 
Many genes were implicated in Sjogren Syndrome etiology and it is a 
polygenic disease. The best documented genetic risk factors of autoimmune 
diseases are polymorphic major histocompatibility complex (MHC) genes.  For 
Sjogren Syndrome, MHC class II genes are of importance, especially HLA-DR 
and HLA-DQ  alleles.  HLA class II haplotypes, the DRB*03-DQB1*02 were 
frequently reported to be linked with the disease (Kang, 1993).  These distinct 
polymorphisms of HLA alleles were associated with differences in autoantibody 
repertoire, especially anti-Ro (SS-A) and anti-La (SS-B) antibodies  (Gottenberg, 
2003; Davies, 2001).  Link with MHC class I genes was also reported.  The higher 
frequency haplotype found was HLA-A24  (Loiseau, 2001).  
Lately, research has focused on finding association between Sjogren 
Syndrome and polymorphic genes that encode molecules involved in the immune 
system, especially cytokines.  Cyokines mediate and regulate immune and 
inflammatory responses and they were suggested to have a role in autoimmune 
diseases including Sjogren Syndrome pathogenesis.  Polymorphism of cytokines 
researched are interleukin 10, interleukin 4, interleukin 6, tumor necrosis factor α 
and tumor growth factor β (Ramos-Casals,2005; Hulkkonen, 2001; Gottenberg, 
2004; Pertovaara, 2004; Youn, 2000). 
Additional candidate gene studies were also undertaken.  Sjogren 
Syndrome was associated with the polymorphisms of mannose binding lectin 
(MBL), Fas/FasL and receptor mononuclear cell attracting chemokine receptor, 
CCR5. (Tsutsumi, 2001, Wang, 2001, Bolstad, 2000, Petrek, 2002; Ramos-
Casals,2005).  Table 1.4 lists the non-MHC genes reported to be associated with 
Sjogren Syndrome. 
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Table 1.4  Polymorphisms of interleukins and other genes associated with 
Sjogren Syndrome  
 
Polymorphic gene Altered polymorphic 
distibution 
Citation 
Cytokine genes 
IL10 increase in G at position -
1082 , C at position -819 , 
C at -592 
Hulkkonen, 2001; Font, 
2002 ; Gottenberg, 2003 
IL4R altered IL4R allele Youn, 2000 
TNFα increase in A at position -
308 
Gottenberg, 2003; 
Pertovaara, 2004 
Other genes 
MBL increase in wild type 
codon 54 
Tsutnami, 2001; Wang, 
2001 
CCR5 decrease in delta 32 
genotype 
Petrek, 2002 
Fas/FasL altered Fas alleles Bolstad, 2002 
 
 
There are recently investigated candidate antigens for a role in Sjogren 
Syndrome etiology.  The most important of these is aquaporins, plasma 
membrane transporters of water.  There is controversial results on the aberrant 
cytoplasmic localization of aquaporin 5 (AQP-5) channel proteins in this disease 
(Tsubota, 2001; Steinfeld, 2002; Beroukas, 2001).  There is one report on the 
reduced expression of aquaporin 3 (AQP-3) in acinar cells in primary Sjogren 
Syndrome patients (Waterman, 2003 ; Ramos-Casals, 2005).  
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1.1.7.3 Associated antibodies 
 
Table 1.5 Autoantibodies described in Sjogren Syndrome patients and their 
corresponding prevalences (Nakamura et al, 2006) 
 
Autoantibodies Molecular weight of the 
corresponding Antigen 
Prevalence in Sjogren 
patients 
Anti-SSA/Ro Ab  SSA/Ro (52-kd / 60-kd) 25-36% 
Anti-SSB/La Ab  SSB/La (48-kd)  13-48% 
anti-centromere Ab centromere protein B (80-
kd)  
centromere protein C 
(140-kd)  
centromere protein H (33-
kd) 
2-19.9% 
anti-alpha-fodrin Ab alpha-fodrin (120-kd) 73-93% 
anti-type-3 muscarinic 
acethylcholine receptor 
Ab 
type-3 muscarinic 
acethylcholine receptor 
(75-kd) 
90% 
 
Sjogren Syndrome is an autoimmune disease, and a wide variety of auto-
antibodes have been described in these patients (Table 1.5). 
In Sjogren Syndrome, especially anti-Ro/SS-A and to a lesser extent anti-
La/SS-B and anti-centromere antibodies are seen.  These are organ non-specific 
antibodies.  Antigens towards these antibodies are 52 kd SSA/Ro, 60 kd SS-A/Ro 
and 48 kd SS-B/La.  Anti-Ro/SS-A and to a lesser extent anti-La/SS-B are 
frequently also found in relatives of the patients.  Anti-Ro/SS-A antibodies are 
found in 65% ; anti-La/SS-B is found in 50% of the patients.  Anti-Lo/SS-A is 
restricted to Sjogren Syndrome but anti-Ro/SS-B can be found in systemic lupus 
erythematosus, rheumatoid arthritis or polymyositis.  The presence of these 
autoantibodies is related to density of lymphocytic infiltrates, the severity of 
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extraglandular symptoms, parotid gland enlargement, early disease onset and 
longer disease duration (Yamamato, 2002). 
Rheumatoid factor is found both in primary and secondary Sjogren 
Syndrome, but the presence of rheumatoid factor is a general feature of 
autoimmune diseases.   
Alpha-fodrin is an apoptotically cleaved form of fodrin, which is a 
membrane skeletal protein found in many tissues.  Antibodies against alpha-
fodrin is found in Sjogren Syndrome sera.  It is not known whether it is a primary 
or secondary event to the disease.  
Based on one theory, these antibodies are produced in the salivary glands 
(Tengner, 1998).  The abnormal localization of anti-Lo and anti-Ro was reported 
several times in disease and stress states.  Surface expression of an antigen 
reactive to these antibodies was shown after irradiation of keratocytes.  This raises 
the possibility that altered localization of antigens after apoptosis can be the 
immunogen in autoimmune responses (Lefeber,1984).  Another theory on the 
production of these antibodies is molecular mimicry.  Sequence similarities of SS-
A/Ro and SS-B/La determinants with retroviral antigens have been reported 
(Kohsaka,1990;Yamamato, 2002).   
Anti-M3 antibody can particularly have a role in the pathogenesis because 
it can cause exocrine dysfunction by blocking neurotransmission (Nakkamura, 
2006; Venables, 2004).  
 
 
 
1.1.7.4 Viruses 
 
Viral infection is one of the most important proposed environmental 
factors.  Viruses of the herpes family are implicated in Sjogren Syndrome 
pathogenesis.  Cytomegalovirus was shown to induce sialadenitis with Sjogren 
Syndrome antibodies in a mouse model (Fleck, 1998).  Epstein barr virus (EBV) 
commonly infects the salivary glands and induces strong T cell responses. 
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Hepatitis C Virus (HCV) infected people present sialadenitis and lymphocytes in 
the gland without other phenotypes of Sjogren Syndrome  (Haddah, 1992).  
Retroviruses, human immunodeficiency virus (HIV) and human T lymphotrophic 
virus (HTLV-1) were also impilicated in this syndrome because they are known to 
infect cells of the immune system and cause immune dysregulation and present 
lymphcytosis.  HIV infected people were shown to exhibit Sjogren like 
syndromes more frequently (Kordossis, 1998).  Sjogren syndrome patients were 
shown to have HTLV-1 antibodies (Terada, 1994).  Novel retroviral genome was 
found in the salivary glands of Sjogren Syndrome patients (Griffiths, 1997).  
These were treated in an antiretroviral manner and improvement in sicca 
symptoms was observed (Steinfeld, 1999;Yamamato, 2002).  
 
1.1.8. Research to relate microchimerism and Sjogren Syndrome 
 
 Microchimerism is the presence of a small population of genetically 
distinct cells in an individual.  Fetal microchimerism is the presence of fetal cells 
in the maternal blood due to their transfer during pregnancy.  There is intense 
research on a possible contribution of fetal microchimerism in Sjogren Syndrome 
pathogenesis, but the results are controversial.  A preliminary research concluded 
that circulating fetal cells are uncommon among the peripheral blood 
mononuclear cells of Sjogren Syndrome patients  (Toda, 2000).  Carlucci et al. or 
Aractingi et al. could not find significant correlation between the disease and 
salivary gland microchimerism (Carlucci, 2001; Aractingi, 2002)  Further 
research identified fetal cells in salivary glands of Sjogren Syndrome patients.  In 
the same article, no difference between patients and controls in relation to 
microchimerism in their peripheral blood was reported (Endo, 2001).  In another 
research fetal cells were found in the salivary glands and bronchoalveolar lavage 
fluid of Sjogren Syndrome patients (Kuroki, 2002).  
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1.2. X Chromosome Inactivation  
 
 
1.2.1 X Dosage compensation 
 
Sex dosage compensation is a mechanism to equalize X chromosome 
expression in females and males.  The term was fırst used by Hermann Muller, a 
Drosophilia geneticist (Muller, 1947).  X dosage compensation is achieved 
through different mechanisms in D. melanogaster, C. elegans, birds and 
mammals.  In fruit flies, it is provided by doubling of male X chromosome 
expression.  In roundworms, expression from each of the X chromosome in 
females is halved.  In mammals, dosage compensation takes place by 
chromosome silencing.  X chromosome inherited from either parent is silenced at 
random, and normal women are thus a mosaic of 2 cell populations (Willard, 
2006; Migeon, 2007). 
 
1.2.2 Discovery of X chromosome inactivation  
 
Murray Barr and Evart Bertram observed that in cat nerve cells, there was 
a dotlike body that stained like chromatin, found near the nucleus, which they 
named “nucleolar satellite”.  They noticed the female specific presence of this 
“sex chromatin body” or “Barr body” and extended their research showing that 
this body was present in a variety of species including humans (Barr, 1949).  This 
female specific feature was used in research of abnormal sexual development.  By 
1954, it was shown that Turner patients had no Barr body, but Klinefelter patients 
had one.  In 1956, it was possible to examine chromosomes directly and it was 
obvious that the number of Barr bodies in an individual was one less than the 
number of  X chromosomes.  At the time, researchers hypothesized that Barr body 
was formed by the crossing of two X chromosomes.  Susumo Ohno proposed that  
Barr body was derived from a single X chromosome showing that there was a 
single condensed chromosome in liver cells from female rats and mice.  This 
chromosome was female specific like the Barr body  (Ohno, 1959).  Liane Russell 
and Ernest Beutler also proposed that only one X was active in female cells.  
Russell came to this conclusion based on her observations of mice with aberrant 
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sex chromosomes (Russell, 1961).  Beutler`s proposal was based on his 
observations that heterozygotes for glucose 6 phophate dehyrdrogenease (G6PD) 
deficiency had mixtures of normal and G6PD deficient blood cells (Beutler, 
1961).   
Mary Lyon who studied the genetic effects of radiation noticed 
unexpected findings in relation to a X-linked coat color gene in mice  (Lyon, 
1953).  The mutation of this gene resulted in death in males and white spotting on 
the coat of female heterozygotes.  This was unusual when compared with other 
coat color genes.  After other relevant findings accumulated, Lyon suggested that 
only one active X is necessary in each female cell.  She proposed that one X is 
inactivated early in embryogenesis and take the appereance of a condensed 
chromosome like the one observed by Ohno.  She suggested that the females are 
mosaics since either the paternal or maternal X is inactivated in each cell.  She 
reasoned the large color patches on the coat of female mice correspond to clones 
of  cells with one parental X inactivated early in development.  She later extended 
her hypothesis to other mammals including humans (Lyon, 1962).  She also 
predicted that this mottling effect should be present for all other X-linked coat 
color genes.  She also hypothesized that this effect should be present in XXY 
males since they are also mosaics (Lyon, 1962).  She noticed heterozygous 
females with the ocular albinism gene mutation partially manifested the disease.  
She also hypothesized that there were regions on X chromosome which were not 
subject to X chromosome inactivation (XCI) meaning pseudoautosomal regions 
and symptoms of Turner Syndrome result from loss of normal two fold dosage of 
these genes.  She also reasoned the unexpected viability of individuals with 
multiple X chromosomes with XCI.  Because it is known that more than two 
copies of a chromosome is not viable (Lyon, 1962).  Lyon performed 
heterozygous mouse breeding experiments to show that only one X-linked coat 
color gene was inactivated in each cell.  The most obvious proof that single X was 
active in each somatic cell and this inactivation was stably inherited came from 
single cloning experiments of skin cells heterozgous for G6PD.  Clones of single 
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cell dilutions derived from these cells expressed either G6PD A or G6PD B  
(Davidson, 1963 ; Migeon, 2007).   
 
1.2.3. Features of Inactive X 
 
One feature of the inactive X is that it is condensed during interphase and 
named as Barr body in other words sex chromatin mass,  although it looks the 
same as its active homologue during metaphase.  The first indicator of an inactive 
X is that it`s late replicating before cell division, which can be determined by 
labeling the chromosomes using a tagged version of thymidine (Morishima, 
1962).  Another feature of inactive X is that it is heterochromatic so 
trancriptionally inactive except its pseudoautosomal regions.  It has 
underacetylated H3 and H4 histones, which is demonstrated with acetylated 
histone specific antibodies.  Inactive X chromosome has a characteristic letter ”C” 
shape with a bend placing the ends of the two arms closer to each other  (Walker, 
1991). This shape is mostly distinguished in the interphase.  The genes on the 
inactive X have methylated CpG islands in their promoter regions.  Latest 
research has shown that active X has twofold methylation at intergenic CpGs 
(Hellman, 2007).  One of the most important features of inactive X is that it 
transcribes X-inactive-specific transcript (XIST).   
 
1.2.4. Clonal Nature of XCI 
 
The inactivation pattern is clonally inherited and irreversible in somatic 
cells.  XCI occurs and is reversible during a limited time durindg embryogenesis 
and then becomes irreversible as shown in stem cell models (Wutz and Jaenisch, 
2000). Adding X chromosomes with hybridization/selection experiments or 
removing Xist with silencing RNA after the critical developmental stage has no 
effect.  The reactivation of silent X only occurs in oocytes during their maturation 
from ovarian germ cells.  Reversal of XCI can be induced to occur also in 
placental cells (Migeon,1986; Migeon, 2005).     
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1.2.5. Timing of XCI 
 
The exact timing of XCI is not known.  There are three proposed models 
for XCI. These models are as shown in Figure 1.3. 
The classical model supports that the X chromosomes are transmitted from 
gametes to embryo fully active and XCI occurs during blastocyst stage coupled 
with differentiation.  This model doesn`t explain how embryo can tolerate twofold 
imbalance of X-linked gene expression.  Paternal X in the sperm is inactived by a 
process of sex chromosome body in other words XY body inactivation.  So 
another hypothesis called the preinactivation hypothesis defends that inactive X of 
the sperm is transmitted to the embryo and and more global silencing occurs in 
the trophoblast while reactivation and random inactivation occur in the epiblast  
(Huhyn, 2001).  It is supported by the finding that in the early cleavage steps of 
embryogenesis, there is some expression from both Xs and the expression from 
the paternal X is increasing (Huhyn, 2003; Mak., 2004).  The de novo inactivation 
hypothesis states zygote inherits active X chromosomes and inactivation starts at 
four-eight cell stage.  In the epiblast, reactivation occurs following random XCI.  
This is based on the observation that two-cell stage embryos have some features 
of active X  (Huhyn, 2004; Migeon 2007).  
 Imprinted XCI is known to take place in marsupial cells (Cooper, 1971; 
Namekawa 2007) and placental cells of some eutherians (Takagi, 1975).  So it 
seems likely that XCI evolved as an imprinted phenomenon, which was later 
modified in eutherians (Graves, 1996). 
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Figure 1.3  Models in relation to the XCI timing in the embryo a) pre-inactivation 
b) de novo inactivation c) classical model (Huhyn, 2004) 
 
1.2.6. Master control region of XCI and its components 
 
Russell was the first to hypothesize that there is a region on X 
chromosome from which XCI initiates and spreads bidirectionally (Russell, 
1963).  In both mice (Russell, 1965) and humans (Therman, 1974, 1979), the 
master control region of XCI was identified observing X-autosome translocations.  
The X-inactivation center (XIC) was first mapped to band Xq13 in humans and D 
region of the mouse X chromosome.  The region was further defined by 
transfecting parts of the putative region into mouse embryonic stem cells to see if 
they could function (Lee, 1999; Heard, 1999: Lee, 1996; Migeon, 1999).  XIC is 
poor in protein-coding genes and it includes many repeats  (Ross, 2005).  Several 
genes involved in XCI were identified in XIC (Figure 1.4).   
The most crucial gene within is Xist in mouse and XIST in humans.  It is 
larger than 17 kb and it codes for a regulatory RNA transcript.  It was identified in 
many eutherians including mice and humans (Brown, 1992; Brockdorff, 1992).  
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However it was not identified in monotremes or marsupials (Duret, 2006).  The 
sequence homology among Xist from different species is less than 50%  (Chureau, 
2002).  However genomic organization, promoter region, transcription start sites, 
tandem repeat and most intron-exon boundries are conserved among species.  
When male mouse embryonic stem cells were transfected with a YAC transgene 
containing XIST, it induced random inactivation in male transgenic mice derived 
from these cells. (Migeon, 1999)  This noncoding RNA is expressed from both 
male and female Xs partially before XCI.  The significance of this low expression 
is not known (Ray, 1997).  It continues to be fully expressed after XCI, so it is 
hypothesized that it can have a function in maintanance of XCI.  Its different 
isoforms exist, which may have a role in regulation  (Ma, 2005).  Its deletions do 
not reactivate the inactivated X since there are other mechanisms of maintanance 
(Brown, 1994).  Induced Xist deletions in mouse, spontaneous human XIST 
mutations such as seen in the cases of people with ring chromosomes and XIC 
transgenes have shown that role of Xist is XCI.   
Another gene within XIC is Tsix which is antisense to Xist.  Mouse Tsix is 
a 40-kb RNA originating 15 kb downstream of Xist and transcribed across the Xist 
locus (Lee, 1999).  Deleting a 65-kb region downstream of Xist results in 
constitutive Xist expression and X inactivation.  Before the onset of X 
inactivation, Tsix is expressed from both X chromosomes.  At the onset of X 
inactivation, Tsix expression becomes monoallelic, is associated with the future 
active X and persists until Xist is turned off.  Tsix is not found on the inactive X 
once cells enter the X inactivation pathway.  Human TSIX produces a >30-kb 
transcript that is expressed only in cells of fetal origin.  Differences in the 
structure of human and murine genes indicate that human TSIX was truncated 
during evolution.  Human TSIX can not repress XIST and is coexpressed with it 
through embryonic development (Migeon, 2001).  It was implicated that Tsix and 
X-inactivation intergenic transcription element (Xite) mutations effect choice and 
counting (Lee,2005; Migeon, 2002). 
A cis element called Xite was found and shown to downregulate Tsix at 
the onset of XCI.  This was suggested as a candidate for X chromosome 
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controlling element (Xce) (Ogowa, 2003).  Before the discovery of Xist, the best 
candidate for XCI was Xce because it effects the randomness of XCI  (Johnston, 
1981; Simmler, 1993). 
 
 
 
Figure 1.4 Elements of Xic  The Xic center that is determined by deletion and 
trangene studies.  Green parts demonstrate genes that give rise to non-coding 
transcripts. Grey parts show protein-coding genes with unknown function in 
relation to XCI.  Black parts indicate parts involved in counting and choice 
determined by targeted deletions.  Mapped Xce implicated in choice is also shown 
(Heard et al, 2004). 
  
1.2.7. Steps of XCI 
 
Steps of XCI include counting, choice, inactivation, spreading and 
maintenance.  In all mammalian cells, all X chromosomes are inactivated but one 
remains active.  The mechanism of XCI seems to depend on determining an active 
X and repressing all the other X chromosomes by a default pathway.  Silencing is 
chromosome wide.  Cis inactivation is mediated by a noncoding RNA molecule 
transcribed from Xist  in XIC.  The molecule spreads along the chromosome from 
which it is expressed and transcriptionally silences it by changing the underlying 
chromosome.    
Counting is the essential first step in general dosage compensation 
mechanims.  A transient interaction is seen between X chromosomes at their Xic 
at the onset of inactivation in mouse embryonic fibroblasts (Xu, 2006; Bacher, 
2006). Whether this transient interaction is a chromosomal cross-talk in relation to 
XCI and relate to counting is not known (Carrel, 2006).  Recently, an X 
chromosome pairing region was found >100kb upstream of Xist (Augui, 2007).    
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Choice is the second step.  It is hypothesized that inactivation is the 
default pathway and XIC on the future active X should be repressed somehow.  
Xist has the features of a housekeeping gene and silencing X chromosomes 
individually is a more complex program than silencing Xist-expressing 
chromosomes since there is only one active X in each diploid cell.  Based on this 
view,  XIC should receive repressory signals for the Xist gene on the future active 
X.  This regulation can be done through DNA elements in the vicinity of Xist 
acting as enhancers or binding sites for trans-acting factors.  The idea of a 
blocking factor that protects the active X from inactivation was proposed (Lyon 
1972).  The support for the existence of an autosomal Xist repressor comes from 
observations that triploid males with 69,XXY chromosomes can have two active 
Xs in contrast to Klinefelter males (Migeon, 2008). 
Another important step in XCI is the spreading of inactivation by 
modifying chromatin bidirectionally.  Spreading and silencing should be 
distinguished and achieved by different domains of Xist (Wutz, 2002).  The 
specific binding of Xist depends on conserved tandem repeat sequences within its 
first exon (Beletskii, 2001).  These sequences can form stem loop structures 
which are recognized by binding factors.  Silencing occurs only at a critical 
window of development.  This was suggested to depend on the different 
processing of Xist RNA during development (Ma, 2005).   
The observation that inactivation spreading is better in X chromosomes 
than autosomes have raised the possibility that there are ``way stations`` that 
enhance spreading (Riggs, 1985; Lyon, 1998).  Line 1 (L1) elements were 
suggested by Mary Lyon as candidates.  Studies of X-autosome translocations 
supported the hypothesis showing the extend of silencing into the autosomes 
varies.  The maximum spreading to autosome observed is 45 Mb from the 
translocation break point.  The spreading can be either continuous or 
discontinuous so the ability of autosomal parts to maintain the inactive state can 
be different  (Sharp, 2002).          
Silencing of X requires its heterochromatinization.  After Xist 
accumulation, transient enrichment of Polycomb-group (PcG) protein complex 
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around the future inactive X occurs.  Than all histone modifications specific to 
active chromatin are lost.  Hypoacetylation occurs, especially globally for H4.  
During spreading of Xist, histones H3 and H4 undergo lysine modificatons 
specific to inactive X.  Lysine of H2B is ubiquitinated before H3 methylation 
takes place.  The signatures specific to active X are acetylation of H3K9 and di-tri 
methylation of H3K4.  The signatures specific to inactive X are methylation of 
H3K9 and di-methylation of H3K4. Variants of histone H2 accumulates and is 
also ubiquitinated.  A PcG protein accumulates around future inactive X and have 
a methylase activity for H3K9 and H3K27 methylation.  BRCA1 was shown to 
localize around inactive X.  It has a ubiquitin ligase acitivity, so it is possible that 
it has a role in H2B ubiquitination  (Heard, 2004). 
The last event in the silencing is CpG island methylation, which is thought 
to play a role in the maintanance of XCI.  Methylated CpGs bind many methyl 
binding proteins which bind transcriptional silencing complexes such as methyl 
CpG binding protein 2 (MeCP2) (Lyon, 2007; Plath, 2002). 
 
1.2.8. Genes escaping XCI 
 
All the genes on the inactive X chromosome are not subject to full 
inactivation.  15% of the genes escape inactivation based on expression patterns 
of 95% of X assayable genes in fibroblast systems (Carrel, 2005).  These escapees 
are variable among species.  With the exception of pseudoautosomal region, most 
genes expressed from the inactive X have less than 15% activity.  It has been 
hypothesized that these sequences are skipped by the spreading of inactivation or 
failure of maintanance (Flippova, 2005 ; Lingenfelter, 1998).      
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1.2.9.Primary and secondary causes of skewed XCI 
 
The choice of the active X is not dependent on parental origin of the 
chromosome or its gene content.  Exceptions include marsupials and nonhuman 
placental tissues in which exclusively paternal XCI takes place which is called 
imprinted XCI.  In normal females, approximately half of the cells inactivate their 
paternal X while the others choose it as active.  When the ratio of the two cell 
populations deviates significantly from a 1:1 distribution, it is called skewed XCI.  
The causes of skewed XCI is classified depending on whether skewing occurs 
primary or secondary to the inactivation event.  Any alteration in the germline 
XIC can hypothethetically cause bias in the initial choice of which X chromosome 
will be inactivated in the germline and these causes of skewing are called primary 
causes (Puck&Willard, 1998). Secondary causes include lethal X-linked 
mutations, X-autosome translocations, aging, twinning, or monoclonal expansion 
of cells.  In the presence of a deleterious mutation on one of the X chromosomes, 
the cells in which this X remains active dies.  In X-autosome translocations, the 
cells in which the translocated X is inactivated dies.  Skewing was observed to be 
increased in twins raising several explanations.  One of them is twining reduces 
the number of cells contributing to the embryo increasing the chance of skewing.  
Skewing can occur as a result of monoclonal expansion of cells with selection for 
cells that carry the mutant X chromosome (Belmont, 1996; Brown, 2000).           
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 1.3.Self tolerance and Autoimmunity 
 
1.3.1 Immune system 
 
1.3.1.1 Clonal theory of Jerne and Burnett 
 
According to Burnet and Jerne`s theory of clonal selection theory of 
antibody formation,  in a certain point of development, clones of lymphocytes are 
produced in central lymphoid organs as a result of heritable changes such as a 
somatic mutation.  Lymphocytes have receptors similar to antibodies in structure 
so antigens stimulate lymphocytes; the corresponding clones of lymphocytes are 
stabilized in secondary lymphocytic tissue and increase in number.  There is a 
developmental process in the primary lymphoid tissue when any clones of 
lymphocytes which carry reactive sites corresponding to body determinants are 
eliminated  (Jerne, 1955 ; Burnet, 1957).  This theory is important not only for the 
clonal selection it proposes, but also for the discovery of immunological 
tolerance.  
 
1.3.1.2 Self tolerance 
 
When antigen binding to T cell receptors (TCR) and B cell receptor (BCR) 
occur, they turn on cell growth and survival pathways leading to clonal 
lymphocyte proliferation and immunity.  These pathways include nuclear factor 
kappa B (NF-қB) activation; Myc activation and phosphoinositide 3 phosphate 
(PI3K) activation of AKT and Ras activation of ERK.  The growth induced by 
antigens is blocked by several mechanisms conferring self-tolerance (Goodnow, 
2008). These mechanisms are designated in Figure 1.5.   
Mechanisms of self-tolerance can be listed as  1) Autoreactive cells can be 
deleted with apoptosis.  2) Autoreactive cells can gain a different receptor by 
receptor editing.  3) The cell can be intrinsically made functionally unresponsive, 
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which is termed anergy.  4) The cell is extrinsically shut off by limiting the supply 
of co-stimuli, cytokines etc.  The cell can also be suppressed by regulatory T 
cells.  Tolerance mechanisms that take place in generative lymphoid organs when 
thymocytes are still immature are called central tolerance.  The tolerance 
mechanisms in peripheral lymphoid organs are called peripheral tolerance 
(Goodnow, 2005). 
 
 
Figure 1.5 Different mechanisms of self tolerance a) T cell deletion through BIM 
induced or FAS activated apoptosis b) Receptor editing by V(D)J recombination 
or by BCR hypermutation c) Receptor downregulation, role of inhibitory 
receptors on T cells; role of phosphatases in increasing the threshold of B cell-
activation and ubiquitin ligases to tag TCR-CD28 or cytokine receptors to 
interfere with signalling d) B cell require B cell survival factor (BAFF); self-
reactive receptors on T cells require survival factor, IL-7.  Costimulation with 
Toll like receptors (TLRs) for B cells; costimulation through CD28 for T cells; 
costimulation of B cells with CD40L on T cells are needed for activation  
(Goodnow et al, 2005). 
 
1.3.2 Autoimmunity 
 
Autoimmune diseases are a diverse group of diseases including more than 
80 conditions with an estimated prevalence of  5% to 8% in the United States, 
effection 14-22 million people.  The common feature of autoimmune diseases 
(AIDs) is that the patients have a defect which leads to the attack of the host`s 
immune system to self-tissues and organs. There are two subgroups of 
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autoimmune diseases, which are systemic and organ specific. Autoimmunity is 
thought to be a complex disease resulting from several genetic sequence variants 
and environmental triggers including infections and stochastic events.  Familial 
clustering and twin concordance studies have shown that AIDs have a genetic 
basis.  Cooccurence of AIDs in individuals and the occurence of different AIDs in 
families support the view that AIDs have common predisposing genetic elements 
and pathogenic pathways (Eaton, 2007; Fox, 2007).   
 
1.3.2.1 Genes associated with autoimmunity 
 
 Studies with sib-pairs, isolated populations and comparing patients and 
controls have shown that there are genetic risk factors for autoimmune diseases  
(Feltkamp, 1999).  In simple diseases, the disease state is determined by a single 
gene.  Common diseases result from a combination of susceptibility alleles.  
Genome-wide associations, linkage studies and candidate gene based approaches 
were performed and several MHC and non-MHC genes were found to contribute 
to predisposition to autoimmunity (Maier, 2008; Welcome Trust Case Control 
Consortium & Autralo-Angolo-American Spondylitis Consortium, 2007).  
Mutations in a single gene can cause autoimmunity, but most autoimmune 
diseases are associated with several sequence variants.  Below, there is brief 
information on some simple genetic traits associated with human autoimmunity  
(Rioux&Abbas 2005).   
Autoimmune regulator (AIRE) was identified as a gene mutated in 
systemic autoimmune disease, autoimmune polyendocrine syndrome (APS-1).  
Patients with this syndrome show autoimmunity against endocrine organs, skin 
and other tissues.  AIRE is a transcription factor and normally it is expressed at 
high levels in several central and peripheral organs and blood cells.  Studies with 
knock out mouse showed that AIRE gene plays a role in the thymic expression of 
organ specific antigens.  This supports a role for AIRE in central tolerance in the 
thymus.   
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 Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory receptor on 
T cells, which binds to B7-1 and B7-2 on APCs to prevent their binding with 
CD28 on T cells.  This prevents the costimulation necessary for activation of T 
cells and promotes anergy.  CTLA4 knockout mouse develops features of 
systemic autoimmunity including enlargement of lymphoid organs and organ 
lympocytic infiltrates.  CTLA4 polymorphism was associated with Graves 
disease, type 1 diabetes (T1D), autoimmune hypothyroidism and other 
endocrinopathies.         
Forkhead box P 3 (FOXP3) encodes a transcription factor of the forkhead 
family and its expression commits naive T cells to become regulatory T cells that 
aid in tolerance induction. Mouse studies have shown FOXP3 mutations cause 
lack of regulatory T cells and lead to systemic autoimmune disease.  FOXP3 is 
also associated with immune dysregulation, polyendocrinopathy, enteropathy and 
X-linked inheritance (IPEX) in humans.  FOXP3 is located within Xp11.23.  
FOXP3 polymorphisms are associated with autoimmune tyroid disease 
susceptibility  (Ban, 2007).       
Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) encodes a 
lymphoid tyrosine phosphatase which aids in T cell signalling and activation.  A 
polymorphism in PTPN22 was identified in type 1 diabetis and also associated 
with rheumatoid arthritis and systemic lupus erythematosus.   
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1.3.2.1.1 X-linked genes associated with immune system 
  
Observation of several immune related pathologies including 
immunodeficiences and immunoproliferative disease associated with the X 
chromosome is critical in understanding the role of X chromosome genes in the 
immune system. These diseases include XLP syndrome (X-linked 
lymphoproliferative syndrome), X-linked recessive combined immunodeficiency 
syndrome (SCID), Hyper-IgM syndrome type I (HIGM 1), Wiskott-Aldrich 
syndrome (WAS) which affect T cells and X-linked agammaglobulinemia (XLA) 
and X-linked recessive anhydortic ectodermal dysplasia with immunodeficiency 
(XEDA-ID) which effect B cells (Murchinick, 2006). 
As above mentioned, FOXP3, implicated in immune dysregulation 
syndrome characterized by dysfunction of regulatory T cells, is X-linked.  A 
number of non-MHC loci found to be associated with AID susceptibility also 
maps to X chromosome (Becker, 1998).  Further, there are reports on X 
chromosome abnormalities implicated in autoimmune diseases (Chagnon, 2006). 
 
1.3.2.2 Molecular Mimicry 
 
It`s observed that there is an association of infectious agents with 
autoimmune diseases.  One of the mechanisms  proposed to explain the role of 
infectious agents in autoimmune etiology is molecular mimicry. 
Molecular mimicry is the cross-reactivity of immune reagents with host 
self  antigens and microbial determinants because of shared structures.  It was first 
observed during monoclonal antibody generation that the phosphoprotein of 
measles virus and a protein of Herpes Simplex virus type 1 (HSV-1) cross-reacted 
with an human intermediate filament protein (Fujinami,1983).  5% of 800 
monoclonal antibodies made against 15 viruses cross-reacted with host self 
determinants  (Bahmanyar, 1987; Oldstone, 1987).  By observing symptoms after 
injecting Hepatitis B virus (HBV) proteins that share sequence similarity with 
myelin basic protein which is known to cause allergic encephalomyelitis, in vivo 
32 
evidence of molecular mimicry was obtained.  In this way molecular mimicry was 
proposed to have a role in autoimmune pathogenesis (Fujinami, 1985). Several 
diseases were implicated to have a molecular mimicry in their etiology (Oldstone, 
1998).  Molecular mimicry is demonstrated in animal models but has not been 
clearly shown in humans (Fairweather, 2004).  
There are other mechanisms explaining the role of viruses in the loss of 
self-tolerance.  One of them is epitope spreading, meaning autoimmune response 
is targeted to a secondary self-antigen after tissue-damage.  Another one is the 
activation of bystander T cells in an antigen-non-specific manner.  This enhances 
the effects of epitope spreading and molecular mimicry.  As well as viruses, drugs 
are also implicated in causing autoimmunity with the drug metabolism forming a 
neo-self (Christen, 2004; Bach, 2005).  Another proposed theory is that 
microorganisms expose self-antigens to immune system by damaging tissues 
(Fairweather, 2004). 
    
1.3.2.3. Female predominance in autoimmunity  
 
 Most of the rheumatic diseases with autoimmune features exhibit higher 
female incidence.  In Table 1.6, AIDs and corresponding female:male ratios are 
listed.  In Figure 1.6, the incidences of selected of AIDs in females and males is 
designated.  The reasons why AID occurs predominantly in women remains to be 
eluciaded.     
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Table 1.6  Ratio of female:male occurence of autoimmune disorders  (Kast, 1977) 
  
Disease Female:Male 
ratio 
Sjogren Syndrome 9:1 
Autoimmune thyroiditis 
(Hashimato`s & Graves) 
9:1 
Primary biliary cirrhosis 9:1 
Systemic lupus 
erythematosus 
8:1 
Chronic active hepatitis 4:1 
Rheumatoid arthritis 3:1 
Chronic idiopathic 
thrombocytopenic purpura 
3:1 
Polymyositis 3:1 
Dermatomyositis 2:1 
Polymyalgia rheumatica 2:1 
Idiopathic Addison`s 
disease 
2:1 
Progressive systemic 
sclerosis (scleroderma) 
2:1 
Idiopathic acquired auto-
immune hemolytic anemia 
3 : 2 
Myasthenia gravis 3 : 2 
autoimmune gastritis (adult 
penicious anemia with 
achlorhydria) 
3 : 2 
Ulcerative colitis 3 : 2 
Chron`s disease 
(granulomatus colitis) 
lower female 
incidence 
2 : 3 
Goodpasture`s disease lower female 
incidence 
1 : 4 
Preiarteritis nodosa 
(vasculitides) 
lower female 
incidence 
1 : 2 
Wegener`s granulomatosis 
(vasculitides) 
lower female 
incidence 
2 : 3 
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Figure 1.6  Incidence of autoimmune disorders by sex a) white bars show 
incidence in woman b) black bars show incidence in men (Fairweather et al, 
2004) 
 
 
 
1.3.1.3.1. Hormones  
 
Hormonal differences between the two sexes have been proposed to 
contribute to the female predominance of autoimmunity.  This was based on 
several observations : 1) Autoimmune diseases are more prevelant in women and 
one of the most distinguishing features of males and females is sex hormones.  2) 
Immune response is sexually dimorphic.  Females show higher immune response 
after infection or vaccination than men.  3) Men who develop autoimmune 
diseases show more severe symptoms than women.  In vitro experiments show 
that these hormones have a modulatory effect on the immune system.  Androgenic 
hormones trigger T helper 1 response and estrogenic hormones stimulate T helper 
2 response.  Pregnancy is a T helper 2 dominant state and failure of this response  
was implicated in pregnancy loss.  Disease status of autoimmune patients changes 
during pregnancy.  Multiple sclerosis, rheumatoid arthritis patients are affected 
positively, in contrast systemic lupus erythematosus worsens.  High estrogen 
states are observed in women with systemic lupus erythematosus and 
androgenization decreases the disease.  In vivo and in vitro experiments give 
contradictory results on the effect of sex hormones.  Sex steroids and immune 
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system seem to have a dialogue.  There are hormone receptors on immune cells 
and cytokine receptors on hormone producing cells.   
Some cytokines can stimulate the hypothalamus-pitiutary-adrenal axis to 
secrete homones.  Some researchers belive the disease severity is observed as a 
consequence of varying exposure to hormones (Lockshin, 2002; Whitacre, 2001; 
Fairweather, 2004;Gleicher 2006). 
 
1.3.1.3.2. Microchimerism  
 
Microchimerism refers to presence of a small number of cells or DNA of 
an individual present in another individual and its possible causes are blood 
transfusions; passage of cells or DNA from the twin during embryogenesis or cell 
passage during pregnancy.  Fetal microchimerism refers to fetal cell passage to 
mother during pregnancy or elective termination. Microchimerism was suggested 
to be critical in female predominance of autoimmunity: 1) It is an important 
immunological challenge being a period of semi-allogeneic graft transplantation 
similar to graft vs. host disease.  2) The incidence of autoimmune diseases are 
high in females and certain autoimmune diseases show increased incidence after 
pregnancy.  The presence of fetal DNA in the blood, mononuclear cells and skin 
of scleroderma patients were investigated and the HLA relationship of the mother 
and the fetus was determined (Arlett, 1998; Nelson, 1998).  There are variable 
reports, mostly favoring the presence of microchimerism in sclerosis.  It was also 
shown that sclerosis patients without male pregnancies have microchimerism in 
their circulation (Lambert, 2007). Microchimerism in skin was studied for patients 
with polymorphic eruption and positive results were obtained.  It was studied in 
liver biopsies of primary biliary cirrhosis (PBC) and thyroid biopsies of 
autoimmune thyroiditis patients and the results were variable.  There are 
accumulated data on microchimerism in both patients with autoimmunity, people 
with non-immune conditions and controls.  There is also data of microchimerism 
in both blood and other tissues.  Maternal microchimerism refers to the presence 
of maternal cell in an individual.  This kind of microchimerism was detected in 
myopathies (Arlett, 2000).  It`s not known whether microchimerism is primary or 
36 
secondary to autoimmunity.  It was hypothesized that microchimeric cells can 
become activated and proliferate in response to an environmental trigger and 
cause autoimmunity.  When a mouse model was treated with a known 
scleroderma causing agent, vinyl chloride, increased levels of microchimeric cells 
were observed in blood. (Christner, 2000).  Fetal cells were detected in the bone 
marrow and ribs of women with male pregnancies, but not in the controls 
(O`Donoghue, 2004).  Another alternative hypothesis for the role of 
microchimeric cells is that they are beneficial aiding in tissue repair of the 
damaged organ.  Microchimeric cells can aid in pathogenesis, repair, or they can 
be normal remnants of pregnancy (Gleicher, 2006). 
 
1.3.1.3.3. X chromosome Monosomy 
 
X chromosome monosomy is a form of aneuploidy with the presence of 
only one X chromosome in an individual`s karyotype and partial monosomy 
occurs when only a portion of cells have one X chromosome.  Recent findings 
show that X chromosome abnormalities can have a role in autoimmunity.  This is 
supported by the following observations.  1) Many genes involved in immune 
response are on the X chromosome.  2) Patients with X chromosome 
abnormalities such as Turner`s syndrome show autoimmune features. 3) 
Mutations in some X-linked genes cause immunodeficiency diseases and display 
autoimmune features (Invernizzi, 2008). 
It was shown that patients with primary biliary cirrhosis, scleroderma  and 
autoimmune tyroid disease have enhanced X monosomy rate in their peripheral 
blood mononuclear cells, especially in lymphocytes (Invernizzi, 2004; Invernizzi, 
2005).  Monosomy rates were not found to be related to disease severity, but to 
age.  This high level of X monosomy in blood cells is not observed in systmic 
lupus erythematosus (Invernizzi, 2007). It was also shown that X chromosome 
loss was preferental in primary biliary cirrhosis (Invernizzi, 2007).      
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1.4 Skewed X inactivation and autoimmunity 
 
1.4.1 Kast and Stewart hypothesis 
 
Kast proposed an explanation for the high female incidence of 
autoimmune diseases based on the forbidden clone elimination stated in Burnet-
Jerne`s theory.  According to this theory, lymphocytes are negatively selected in 
the thymus, MHCs being the major survival determinants (Burnet 1959, Jerne, 
1971).  Some activity as survival determinants was also proposed for any antigen 
at a generative site (Kast, 1975).  Kast proposed a mechanism other than classical 
patterns of inheritance, disturbance in XCI, may have a role in female 
predisposition to autoimmunity (Kast, 1977).  Stewart developed this hypothesis 
in systemic lupus erythematosus by stating that differences between sexes in the 
self-antigen presentation profiles to the immune system due to XCI mosaicism 
can account for the female preponderance (Stewart, 1998).  According to this 
theory, skewed XCI in the thymus can lead to the escape of autoreactive 
lymphocytes specific for self antigens expressed from one parental X and this can 
lead to autoimmunity (Kast, 1977; Stewart, 1998).  This results because naive T 
cells can not be selected for alleles expressed from one X chromosome because 
there is XCI skewing in the dendritic cells that are localized on the path the naive 
lymphocyte follows during negative selection (Stewart, 1998).   This hypothesis is 
illustrated in figure 1.7.  High frequency of skewed XCI was reported in the blood 
of autoimmune patients: scleroderma, autoimmune tyroid disease, pre-eclampsia 
patients (Ozbalkan, 2005; Ozcelik, 2006, Yin, 2007; Uz, 2006).  No significant 
correlation was found between skewed XCI and the occurence of primary biliary 
cirrhosis, systemic lupus erythematosus, type 1 diabetis and multiple sclerosis 
(Miozzo, 2007; Huang, 1997; Chitnis, 2000).     
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Figure 1.7 Consequences of skewed XCI of thymic cells.  The thymus cells 
displaying skewed XCI are demonstrated.  As a normal physiological event, 
during tolerance induction of naive T cells with dendritic cells exhibiting random 
XCI, naive T lymphoctyes are tolerized for genes expressed from both X 
chromosomes.  However when skewing of XCI occurs in dendritic cells, naive T 
cells which are reactive to antigens from one X are deleted.  However T cells 
reactive to antigens from the other X, which is exclusively or almost exclusively 
inactivated by the dendritic cells, exit the thymus nontolerized and autoreactive to 
self antigens. 
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1.5. Aim and Strategy 
 
It was proposed that skewing of XCI in the hematopoietic cells may cause 
failure in representation of antigens of one X by the antigen presenting cells 
(APC) in the thymus and result in autoimmunity. This was hypothesized based on 
the higher female incidence of most of the autoimmune diseases and XCI being a 
major sex difference (Kast,1977; Stewart,1998). A positive correlation between 
skewed XCI and a number of autoimmune diseases is demonstrated (Ozbalkan, 
2005; Ozcelik, 2006; Yin, 2007; Uz, 2006). Sjogren Syndrome is an autoimmune 
disease with unkown etiology and it shows one of the highest female 
prependorances.  To test whether disturbances in XCI may play a role in the 
pathogenesis of Sjogren Syndrome, we genotyped a polymorphic repeat in the 
human androgen receptor (AR) gene to determine XCI profiles of Sjogren patients 
and controls. (Allen, 1992). 
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CHAPTER II: MATERIALS AND METHODS 
 
2. MATERIALS AND METHODS 
 
2.1 Samples 
 
2.1.1 Control Samples 
 
Caucasian females comprised of 160 Turkish healthy unrelated volunteers 
is the control group in this study.  The mean age for Turkish controls at analysis 
was 46±10.0 (mean±SD). There was no clinical evidence or family history of 
autoimmune or inflammatory joint disease.  The XCI profiles of this group was 
used to compare with those of Sjogren Syndrome patients (Ozbalkan, 2005; 
Ozcelik, 2006).  
 
2.1.2 Sjogren Syndrome Patient Samples 
 
Caucasian women (n=78) diagnosed with Sjogren Syndrome were referred 
to Bilkent University, Facutly of Science, Molecular Biology and Genetics 
Department (Ankara, Turkey) by Zeynep Özbalkan at the Ankara Numune 
Education and Research Hospital, Rheumatology Clinic (Ankara, Turkey). Their 
venous blood samples were transferred in EDTA collection tubes. Informed 
consent forms were obtained from all subjects.  These samples were genotyped 
and their XCI patterns were determined.     
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2.2 Materials  
 
2.2.1  Primers 
 
The sequences of the primers used in polymerase chain reaction (PCR) are : 
primer 1,  5'- GTC CAA GAC CTA CCG AGG AG-3'; and primer 2,  5'-CCA 
GGA CCA GGT AGC CTG TG -3'.  The primers were synthesized by IONTEK 
(Istanbul, Turkey).  The region amplified by the primers is as designated in  figure 
2.1. 
 
 
2.2.2 Enzymes 
 
Thermus aquaticus (Taq) DNA polymerase was used in the PCR reactions.  
Restriction digestion enzymes, RsaI and metylation sensitive HpaII  were used in 
the digestion reactions.  All enzymes were purchased from MBI Fermentas Inc. 
(Amh, NY, USA).  The recognition sites of restriction digestion enzymes are as 
designated in figure 2.1. 
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CGAGATCCCGGGGAGCCAGCTTGCTGGGAGAGCGGGACGGTCCGGA
GCAAGCCCAGAGGCAGAGGAGGCGACAGAGGGAAAAAGGGCCGAGC
TAGCCGCTCCAGTGCTGTACAGGAGCCGAAGGGACGCACCACGCCAG
CCCCAGCCCGGCTCCAGCGACAGCCAACGCCTCTTGCAGCGCGGCGG
CTTCGAAGCCGCCGCCCG 
 
... 
 
AACTCTTCTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGAAGTAGGTG
GAAGATTCAGCCAAGCTCAAGGATGGAAGTGCAGTTAGGGCTGGGAA
GGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGAGGAGCTTTCCAG 
            forward primer (RS6) 
AATCTGTTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGGGCCCCAG 
                                                                                            HpaII restriction site 
GCACCCAGAGGCCGCGAGCGCAGCACCTCCCGGCGCCAGTTTGCTGC 
                                                                                 HpaII restriction site 
TGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
                                              CAG repeat 
AGCAGCAGCAGCAGCAGCAGCAGCAGCAAGAGACTAGCCCCAGGCA
GCAGCAGCAGCAGCAGGGTGAGGATGGTTCTCCCCAAGCCCATCGTA
GAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTC 
                                        reverse primer (RS7) 
 
ACAGCCGCAGTCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCC
CAGAGCCTGGAGCCGCCGTGGCCGCCAGCAAGGGGCTGCCGCAGC 
 
... 
 
GCTGTAGCCCCCTACGGCTACACTCGGCCCCCTCAGGGGCTGGCGGGC
CAGGAAAGCGACTTCACCGCACCTGATGTGTGGTACCCTGGCGGCAT
GGTGAGCAGAGTGCCCTATCCCAGTCCCACTTGTGTCAAAAGCGAAAT
GGGCCCCTGGATGGATAGCTACTCCGGACCTTACGGGGACATGCG 
 
 
 
Figure 2.1 AR genotyping amplicon (287 bp). Sequence of Homo sapiens AR 
exon 1 on the X chromosome between 66680599-66860844 bp.  is shown.  
Reference assembly is NC_000023.9 in NCBI and  ENSE00001326500 in 
Ensembl.  HpaII digestion sites and CAG repeat regions are designated (Allen, 
1992). 
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2.2.3 Oligonucleotide 
 
The length of DNA fragments were estimated by comparing to known molecular 
weight standards that had been run on the same gel. pUC Mix Marker 8 
(#SM0303) (0.1µg/µl) and Massruler DNA Ladder (#SM0403) Mix were used as 
markers and purchased from MBI Fermentas (Amh, NY, USA) The sizes of the 
fragments are given in figure 2.2.    
 
           
 
Figure 2.2 Sizes of the fragments of pUC Mix Marker 8 and MassRuler DNA 
Ladder Mix and appearance on gel electrophoresis.  
 
 
 
44 
  
2.2.4.Chemicals,  Reagents, Kits 
   
The chemicals and reagents used in this project and the suppliers are listed in 
table 2.1. 
 
Table 2.1 List of chemicals and reagents used in this study 
 
Experiment Reagent or Chemical Company 
Nucleospin® DNA 
Isolation Kit (Buffers 
B3, BE, BW, B5) 
Macherey-Nagel Inc., 
PA,USA 
Proteinase K Appligene-Oncor, USA 
DNA Isolation 
100% Ethanol (EtOH) Merck, Frankfurt, 
Germany 
Agarose Gel Preparation Agarose Basica LE, EU 
Bisacrylamide Sigma, St. Louis, MO 
Acrylamide Sigma, St. Louis, MO 
APS Carlo Erba, Milano, Italy 
Polyacrylamide Gel Preparation 
TEMED Carlo Erba, Milano, Italy 
6X MassRuler™ DNA 
Loading Dye 
MBI Fermentas, Amherst, 
NY, USA 
Ethidium Bromide 
(EtBr) 
Sigma, St. Louis, MO, 
USA 
 
EDTA (pH 8.0) Carlo Erba, Milano, Italy 
Tris Merck, USA 
Gel Electrophoresis 
100% glacial acetic 
acid 
Sigma, USA 
Restriction Digestion Tango Buffer (10X) MBI Fermentas, Amherst, 
NY, USA 
dNTP (10 mM) MBI Fermentas, Amherst, 
NY, USA 
MgCl2 (25 mM) MBI Fermentas, Amherst, 
NY, USA 
PCR  
Buffer (10X) MBI Fermentas, Amherst, 
NY, USA 
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2.2.5 Standard solutions and buffers 
 
50X TAE (Tris-acetic acid-EDTA): 242gr Tris, 57.10 ml acetic acid, 37.2 gr 
EDTA.  The volume was adjusted to 100 ml by adding ddH2O and pH is adjusted 
to 8.0   
 
1X TAE (Tris-acetic acid-EDTA): 40mM Tris-acetate, 2 nM EDTA, pH 8.0. 
 
Acrylamide:Biacrylamide Stock Solution (30%): 29.5 gr acrylamide, 0.44 gr 
bisacrylamide. The volume was adjusted to 100 ml by adding ddH2O. 
 
APS solution (10%): Prepared freshly with 0.1gr ammonium persulfate in 1mL 
ddH2O. 
 
Ethidium bromide: 10mg/ml in water (stock solution) 30 ng/ml (working solution) 
 
6X MassRuler™ DNA Loading Dye : 10mM Tris-HCl (pH 7.6) 0.03% 
bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol 60mM EDTA. 
 
pUC Mix 8 Marker : 1 volume of pUC Mix 8 Marker, 1 volume of 6X 
MassRuler™ DNA Loading Dye and 4 volumes of ddH2O. 
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2.3 Methods 
 
2.3.1 Sample collection 
 
Venous blood samples obtained from Sjogren Syndrome patients and 
controls were transported in EDTA tubes.  Their entry to the lab was recorded.  
They were seperated as 1ml aliquots to eppendorf tubes (1.5 ml).  The bloods (1-3 
eppendorfs) were stored at -80oC.  200 μl blood was seperated for DNA isolation 
and stored at -20oC.   
 
2.3.2 DNA Isolation from venous blood 
 
DNA from venous blood was isolated by using Nucleospin™ Blood kit 
(Macherey-Nagel Inc., PA, USA) (#740 951.250) according to the protocol of the 
manufacturer.  The starting blood sample was 200 μl and the resulting material 
was 100 μl elution buffer containing DNA.    The efficiency of this kit is 
typically 40-60ng/µl genomic DNA with an A260/280 value of 1.6-1.9.     
Blood samples preequilibrated to room temperature were lysed with 
proteinase K and lysis buffer vortexing and heating at 70 oC.  Adjusting of DNA 
binding was performed with ethanol (100%).  DNA was bound to silica 
membrane which was then washed with buffers.  With centrifugation residual 
ethanol was removed.  Using preheated 70 oC elution buffer, DNA was eluted. 
The concentrations and purity values of DNA were measured with 
spectrophotometric reading using NanoDrop™ ND-1000 UV-Vis 
Spectrophotometer. 
In the process, 2 µl of the sample was used for measurement.  2 µl elution 
buffer was used as blank.  The integrity of the DNA samples were controlled with 
1% agarose gel electrophoresis.    
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2.3.3 AR genotyping 
 
To determine the XCI status of individuals, androgen receptor (AR) 
genotyping was performed. (Figure 2.3)  AR locus spans a region larger than 90kb 
and it has been mapped to Xcen-Xq13. Its cDNA has an open reading frame of  
2,751 nucleotides and its protein has 917 amino acids. In its first exon there is an 
inframe CAG repeat that codes for 11-31 glycine residues.  
A 280 bp region (nucleotides 229-508) of the AR is amplified. (Figure 2.3)  
This region includes a highly polymorphic trinucleotide repeat (20 alleles, 90% 
heterozygosity) and HpaII and HhaI sites less than 100 bp away from this short 
tandem repeat (STR).  The proximity of STR to enzyme target sites gives an 
opportunity to distinguish between maternal and paternal alleles and to determine 
their XCI status.   
HpaII and HhaI are methylation sensitive enzymes which have target sites 
with CpG.  Cytosine residues in CpG islands, which are clustered at the 5` of 
genes are methylated in the inactive X.  AR genotyping relates methylation of 
HpaII and HhaI sites in the AR locus with XCI.  (All enzyme sites are consistently 
methylated on the inactive X, but one or more enzyme sites are unmethylated on 
the active X.)  In AR genotyping, DNA is first digested with HpaII and/or HhaI 
and than a region including the enzymes site and the repeat is amplified.  The 
enzyme target sites on the active X chromosome, which have unmethylated 
cytosines will be cleaved and no amplicon will be observed for the active X.  
Since they are methylated, the sites on the inactive X will not be cleaved, so an 
amplicon will be observed for the inactive X.  The X inactivation patterns can be 
determined in females who are informative at their CAG repeat (Allen, 1992).    
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  Figure 2.3 Establishing random and skewed XCI with AR genotyping 
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2.3.3.1 Restriction Enzyme Digestion 
 
For each sample, two restriction enzyme digestion mixtures were 
prepared, each of which have a total reaction volume of 20 μl.  The amount of 
DNA was adjusted to 150-250 ng in the digestion mixture. 2 µl of Y tango buffer 
with BSA (#BY5) (33mM Tris-acetat (pH 7.9), 10mM magnesium acetate, 66 
mM ptoasium acetate, 0.1 mg/mL BSA) (10X) was added to adjust the final 
buffer in the mix to 1X.  0.2 µl RsaI (#ER1122) (10U/µl) (5`-GT↓AC-3`) was 
included in both mixes to adjust its concentration to 2U in the final mix.  RsaI has 
target sites outside the PCR product and it makes the DNA more accessible.  0.8 
µl HpaII (#ER0512) (10U/µl) (5`-C↓CGG-3`), which is methylation sensitive, 
was included in the second mix to adjust its concentration to 8U in the final mix.  
The reactions were incubated at 37oC in the incubator overnight.  Heat 
inactivation of the reactions was performed at 70oC for 10-15 minutes in the 
heater. Restriction digestion products were stored at 4oC for further use. First 
digestion is used for AR genotyping, the second digestion was used to assess XCI 
pattern. Negative controls were performed without DNA and the positive controls 
were performed with male DNA.  
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2.3.3.2 Polymerase chain reaction (PCR) 
 
 
The digest amount was adjusted to 50ng-100ng in the PCR mix.  The final 
concentrations in the PCR mix were 10mM for MgCl2 (25 mM), 0.12 for dNTP 
(10mM), 10pmol for the primers (10pmol/µl), 1U for the Taq polymerase 
(#EP0402) (5U/ µl), 1X for the buffer (10X) (750mM Tris-HCl (pH 8.8 at 
25oC),200 mM (NH4)2SO4, 0.1% (v/v) Tween 20).  In order to amplify the desired 
region, 94oC 5 min initial denaturation step was performed.  PCR reactions were 
performed in Techne™ Techgene thermal cycler.  This was followed by the 
amplification step including 30 cycles of 94oC 30 sec denaturation, 58oC 30 sec 
annealing, 72oC 30sec extension.  Final extension was performed at 72oC for 5 
min. Amplicons were controlled with 1.5% gel electrophoresis. 
 
 
2.3.3.3 Visualization 
 
2.3.3.3.1 Agarose gel electrophoresis  
 
1% agarose gel electrophoresis was performed to check whether total 
human genomic DNA was isolated.  2 μl of MassRuler DNA Ladder mix 
(#SM0403), 2 μl DNA with 1 μl 6X MassRuler™ DNA Loading Dye (#R0611) 
(103 ng/µl) was loaded.  
To visualize the PCR products for the determination of the success, 1.5% 
agarose gel electrophoresis was performed. 4 µl of pUC Mix Marker (#SM0301) 
(0.5 µg/µl) and 5 μl of sample with 6X MassRuler™ DNA Loading Dye (5:1 
ratio) were loaded. 
The gels were prepared by dissolving required amount of agaose in 1X 
TAE.  Required amount of EtBr (10mg/mL) was added.  The gel was run in 1X 
TAE for the required amount and time.  UV transilluminator was used during 
visualization and photography. 
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 2.3.3.3.2 Polyacrylamide gel electrophoresis (PAGE) 
 
The maternal and paternal alleles were resolved using 8% PAGE 
(polyacrylamide gel electrophoresis). 8% PAGE gel solution for pouring two gels 
(60mL) was prepared by adding the reagents in the following order: in order to 
prepare 16 ml acryamide: bisacrylamide solution (30%), 6 ml 10X TAE, 500 µl 
10% APS, 40 µl TEMED and 37,5 ml ddH2O were included. 
The solution solidifies for 1 hour and the gels are attached to the vertical 
setting.  PCR product with the loading dye is loaded.  pUC Mix Marker is used as 
a marker.  The gels were run at 20 Watt per gel in 1X TAE buffer for 2 hours.  
They were stained in buffer containing EtBr for 5 minutes, washed in ddH2O for  
another 5 minutes.  
 
2.3.3.4  Densitometric and Statistical Analysis 
 
Multi-Analyst software version 1.1 (Bio-Rad, Hercules, CA) was used for 
the densitometric analysis.  Densitometric analyses included normalization of the 
ratios based on the undigested samples.  Normalization was performed by 
dividing the allele ratio of the digested sample by the allele ratio of the undigested 
sample.  This calculation is performed as a correction for the preferential 
amplification of the shorter allele.  The results of the Sjogren Syndrome and 
control group were compared by χ2 test with Yates` correction and Fisher`s exact 
test.  In addition, odds ratio value was calculated in the 95% confidence interval.  
Power analysis was performed to estimate the sample size that is needed to make 
accurate statistical judgements.  The minimum effect size was determined based 
on the results of XCI status studies of our group for other autoimmune diseases  
(Ozbalkan, 2005; Ozcelik, 2006 ; Uz, 2006).  The significance level was set as  
α=0.05 and the power was set as β=0.1. 
 
 
52 
 CHAPTERIII: RESULTS 
 
Androgen receptor assay was performed for XCI status determination of 
Sjogren Syndrome patients and healthy controls. Methylated inactive X 
chromosome is resistant to digestion by methylation specific HpaII enzyme, while 
unmethylated X chromosome is prone to digestion.  There are highly polymorphic 
triplet repeats adjacent to HpaII methylation sites in the androgen receptor gene, 
which provide a method to distinguish the two alleles and their methylation status.  
Figure 3.1 demonstrates the gels of uninformative, random and skewed 
XCI patterns.  Uncut (U) refers to DNA amplified prior to HpaII digestion, 
genotyping for the polymorphic repeat.  Cut (C) refers to DNA amplified after 
HpaII digestion, giving information on the XCI status.  The individuals, who are 
not polymorphic in the CAG repeat within the amplified region of AR gene were 
uninformative and not included in the densitometric and statistical analysis.  For 
informative samples, densitometric analysis was performed as indicated in the 
methods section.  04-474 and 04-476 are examples of informative samples, 04-
473 demonstrating random and 04-476 demonstrating skewed XCI.  
Skewed XCI refers to a concentration difference of more than 80% 
between the two alleles and extremely skewed XCI refers to a concentration 
difference of more than 90%.  (Naumova et al., 1996). 
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M      04-473                04-474             04-476 
HpaII           -           +          -          +          _        + 
 
 
 
Figure 3.1   XCI inactivation status in Sjogren Syndrome patients.  Polymerase 
chain reaction products from the androgen receptor methylation assay 
demonstrate random X chromosome inactivaton pattern in sample 04-473 (allele 
ratio 64% : 36%) and skewed pattern in sample 04-476 (100% : 0%). Sample 04-
474 is not informative for the androgen receptor polymorphism.  For each sample, 
DNA was either undigested (-) or digested (+) with the methylation-sensitive 
restriction enzyme HpaII. Marker (M; pUC mix 8[331-bp and 242-bp])   
 
XCI patterns of 78 Sjogren Syndrome patients were studied and 51 of 78 patients 
were informative (65.4%).  The control group comprised of females with no 
autoimmune condition.  XCI status of 160 controls were studied and 124 were 
informative (77.5%) Extreme skewing (>90:10) was observed 3 out of 51 
informative patients (5.9%) and in 3 of 124 (2.4%) informative controls.  Skewing 
(>80:20) was observed in 10 of (8.1%) 124 informative controls and in 8 of 51 
informative patients (15.6%).  Statistical verification of the significance of 
correlation was assesed with the odds ratio and P value. The probability value was 
calculated with Fisher`s exact test. The odds ratio and P-value for extreme 
skewing is  P=0.3592 and OR=2.5208 with 95% CI: 0.4915-12.9289.  The odds 
ratio and P-value for skewing is P=0.17 OR=2.1209 with 95% CI: 0.7852-5.7289. 
These results favor that there is not a statistically significant correlation between 
skewed XCI and Sjogren Syndrome.   
Power analysis was performed to estimate the sample size that is needed to 
enable accurate statistical judgements.  The estimated sample size needed to test a 
difference of 0.18 of extreme skewing between patient and control samples with a 
power of 0.9 at a significance level of 0.05 is 47 Sjogren Syndrome and 113 
54 
control samples.  The estimated sample size needed to test a difference of 0.27 of 
skewing between patient and control samples with a power of 0.9 at a 
significiance level of 0.05 is 36 Sjogren Syndrome and 87 control samples.  The 
analysis shows that the sample size used for this experiment is adequate to make 
accurate statistical judgements.     
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Table 3.1 Proportion of Sjogren Syndrome patients and controls with skewed 
XCI 
 
Degree of skewing (%)                       No. (%) observed with skewing 
     Sjogren  Syndrome        Controls 
                                                            patients   (n=51)              (n=124) 
90+     3 (5.9)                    3 (2.4) 
80-89%    5 (9.9)                           7 (5.6) 
70-79%    14 (27.5)  22 (17.8) 
60-69%    9 (17.7)  29 (23.4) 
50-59%    20 (39.2)  63 (50.8) 
_________________________________________________ 
For comparison by χ2, P= 0.2 (>80% skewing); P= 0.4 (>90% skewing) 
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CHAPTER IV: DISCUSSION 
 
Female predominance is a characteristic of most autoimmune diseases. 
(Whitacre, 2001).  In recent decades, candidate mechanisms that could be 
important in autoimmune disease pathogenesis have been studied. Currently there 
are explanations for the female predominance in autoimmune diseases. These 
include genetic traits associated with autoimmunity (Rioux and Abbas, 2005) and 
pregnancy related microchimerism (Arlett, 1998; Nelson, 1999).  Another sex 
specific feature of females is XCI and it is known that skewed XCI can influence 
manifestations of X-linked disorders in females (Lyon, 2002).  The hypothesis 
that skewed XCI in the thymus can cause defects in negative selection and lead to 
autoimmunity was proposed. (Kast, 1977; Stewart, 1998)   
Thymocytes are negatively selected in the thymic parencyma and the 
selecting elements appear to be derived from the bone marrow and are dendritic 
cells.  If the thymic dendritic cell population exhibits skewed XCI, T cells specific 
for certain X antigens will not be deleted.  This hypothesis assumes that the initial 
breakdown in tolerance involves an X-linked autoantigen expressed in peripheral 
site of the body.  In a recent report, lack of expression of one splice variant of 
proteolipid protein (PLP) protein in the thymus was shown to be related to 
susceptibility to autoimmunity (Klein, 2000).  This  illustrates a role of defective 
thymic negative selection in autoimmunity.  Since proteolipid protein is X-linked, 
it also accounts for the hypothesis stated above. 
Loss of mosaicism based on X chromosome skewing was shown to 
correlate with autoimmunity in several AIDs (Ozbalkan, 2005; Ozcelik, 2006; Uz, 
2006; Yin, 2007).  These reports supported that factors associated with loss of 
mosaicism based on X chromosome skewing could account for a significant 
proportion of these autoimmune diseases.  
Currently, the relationship between skewed XCI and AIDs is not known.  
Skewing can be either secondary to breakdown of self-tolerance or it can be a 
causative factor in the breakdown of self-tolerance.  We currently believe the 
second view is more promising since skewing ratios of patients are not mild. 
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XCI skewing can result either from primary or secondary reasons. 
Whether skewing of XCI patterns are transmitted to offspring in humans was 
researched on the hypothesis that an X-linked locus can alter initial random 
inactivation.  No supporting evidence was obtained  (Minks, 2008; Bolduc, 2008).  
The secondary reasons of XCI include X-linked lethal mutations, X-autosome 
translocations, aging, twining or monoclonal expansion (Brown, 1999).  We 
believe that deleterious X-linked mutations can account for skewing leading to 
autoimmunity.  This view is supported by the observation that recurrent 
spontaneous abortions are increased in AIDs and skewed XCI was associated with 
recurrent spontaneous abortions (Bagislar, 2006; Shelton, 1994).  If the cause of 
skewing is indeed a X-linked deleterious mutations as hypothesized, this should 
be inherited from the mother unless they occur de novo in gamategenesis.  An X- 
linked lethal mutation causes skewing in the mother and it is lethal for a male 
infant.  This kind of skewing was reported in X-linked immunodeficiency where 
males have a survival disadvantage and heterozygous females have XCI skewing  
(Puck&Willard, 1998).  We believe deleterious X-linked mutations and their 
differential expression patterns could lead to skewing, conferring a disadvantage 
on blood cells  (Uz, 2007 ; Ozcelik, 2008). 
Although extremely skewed XCI is rare in normal population, it does not 
always lead to the development of disease.  To provide an estimate of the 
frequency of individuals in the general population, XCI status of 1,005 unaffected 
individuals was determined.  The percentage of population with skewed XCI was 
found to be 8.8% and with extremely skewed XCI was found to be 1.8% (Amos-
Landgraf, 2006).  There are also other proposed factors for autoimmune etiology 
other than correlation with skewing.  A subsequent event such as environmental 
exposure to viral, chemical and other agents may trigger autoimmunity.  The co-
inheritance of genetic susceptibility factors for example functional variants of 
molecules involved in immune tolerance may exacerbate the effects of skewed 
XCI leading to autoimmunity. 
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Sjogren Syndrome is an autoimmune disorder with one of the highest 
female prependorance and unknown etiology.  It has been associated with genetic 
factors such as HLA-DR/HLA-DQ, cytokine and other gene polymorphisms 
(Hulkkonen, 2001; Gottenberg, 2004; Pertovaara, 2004; Youn, 2000; Tsutsumi, 
2001, Wang, 2001, Bolstad, 2000, Petrek, 2002).  Environmental factors, 
especially viral infections have been reported as causative factors  (Fleck, 1998; 
Haddack, 1992; Kordossis, 1998;Tereda, 1994;Giffiths, 1997).  There are also 
controversial reports on the role of microchimerism in Sjogren Syndrome (Toda, 
2000; Kuroki, 2002; Endo, 2001).  In this research, a potential correlation 
between skewed XCI and Sjogren Syndrome was investigated.  Patients showed 
skewing patterns comparable to that of controls in their blood cells.  Our results 
did not support a correlation between Sjogren Syndrome and skewed XCI based 
on the P value and odds ratio calculated.  Our sample size was adequate to make a 
true statistical verification based on hypothesis testing.        
Although the role of X mosaicism in breakdown of self tolerance caught 
attention, X inactivation patterns comparable to those of control women were 
observed in the blood from females with primary biliary cirrhosis, multiple 
sclerosis, juvenile diabetes and systemic lupus erythematosus (Miozzo, 2007; 
Knudsen, 2007; Chitnis, 2000)  These results display that other reasons than XCI 
may have role in the pathogenesis of these diseases. For example, molecular 
mimicry is known to have a role in the initiation of the primary biliary cirrhosis 
(Kaplan, 2005).  Based on our results, we can conclude other factors can trigger 
Sjogren Syndrome, other than skewed XCI based mosaicism. 
The tissues of an organism are accepted to reflect the same XCI pattern 
since inactivation process takes place very early during development.  However 
there can be exceptions to this.  It has been showed that although there is a 
significant association of the X inactivation ratios between each tissue in younger 
individuals, there are significant variations in elder individuals (Sharp, 2000; 
Busque, 1996).   It was observed that there can be variation in XCI patterns 
among tissues (Rosemary, 1994).  These results emphasize the role of secondary 
selection events leading to skewing.  We can suspect that the patterns of skewing 
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in blood cells does not demonstrate the skewing pattern of dendritic cells in the 
thymus.  However this is unlikely because it was observed tissues of mesodermal 
origin do not display differences in X inactivation patterns (Chitnis, 2000).  
Another consideration is that tissue microenvironments may exhibit skewed XCI 
because of a small number of founder cells even though the tissue as a whole is 
not skewed.  If this is the case, this can not be reported by working with blood 
cells.  Our group studied buccal mucosa, hair and effected tissues of SSc and 
AITDs.  We can further confirm our findings by studying other tissues such as 
thymic tissue sections. (Chitnis, 2000).  
  In a recent study, the X chromosome skewing status of multiple sclerosis 
patients were assessed and compared in two subgroups of multiple sclerosis.  
They concluded there was a significantly higher degree of skewing in progressive 
multiple sclerosis than relapse remitting subgroup. (Knudsen, 2007)  Our data can 
further be used to extrapolate the differences in the degree of X chromosome 
skewing in primary and secondary Sjogren Syndrome patients. 
X inactivation assay we used in this research is AR genotyping.  There are 
various assays to determine X inactivation pattern based on a marker.  Assays 
based on variant proteins or common exonic polymorphisms to assess expression 
are direct assays.  AR genotyping is an indirect assay which utilizes a DNA repeat 
polymorphism and is based on the presumption that CpG island which is the 
target of HpaII is always methylated in the inactive X.  These kinds of DNA 
assays are highly informative because the polymorphisms in the nontranscribed 
regions of the genome can be used.  They are also more rapid and suitable for 
research in which establishing large informative number is more important than 
determining slight changes in X inactivation status.  AR locus has a 
heterozygosity of >90% and a high degree of accuracy with a variance on 
repeated assays is around 4%. (Chen, 2007; Ozcelik, 2007; Migeon, 2007)       
 
 
 
 
60 
 CHAPTER V: FUTURE PERSPECTIVES 
 
In this research, we tested the hypothesis that disturbances in XCI may 
have a role in the etiology of Sjogren Syndrome.  However our results does not 
support a correlation between skewed XCI and Sjogren Syndrome.  The results of 
our group for two other autoimmune diseases, scleroderma and autoimmune 
thyroid disease favor a role of XCI in the loss of tolerance.  The view of our group 
is that X-linked mutations can have a role in skewed XCI based on secondary 
selection events. A research strategy of our group was to conduct a high-density 
microarray analysis including 1618 nonsynonymous, 1091 synonymous and 2802 
intronic SNPs on X chromosome and 166 SNPs on autosomal chromosomes that 
are known to be associated with autoimmune diseases. Exonic SNPs 
corresponded to 783 genes and intronic ones corresponded to 160 genes.  
Experimental part included 465 AIDs and 2 Sjogren Syndrome patient samples 
with extremely skewed XCI was included in this study.  This study was designed 
to raise putative genes involved in AIDs by determining allelic frequencies and 
copy number variations.  
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 CHAPTER VII. APPENDICIES 
 
Appendix A The list of Sjogren Syndrome patients and their XCI pattern 
 
Number  Sample 
XCI 
Pattern 
90+   5.9%   
1 1 04-476 100 
2 2 07-1057 95 
3 3 07-1054 90 
80-89   9.9%   
4 1 05-543 86 
5 2 07-1059 85 
6 3 04-472 84 
7 4 04-479 80 
8 5 07-1041 80 
70-79 27.5%   
9 1 05-279 76 
10 2 05-545, 05-571 78,7 
11 3 07-1062 75 
12 4 07-1064 75 
13 5 07-1066 75 
14 6 07-1068 75 
15 7 05-008 74 
16 8 04-488 73 
17 9 05-567, 07-1046 73, 75 
18 10 05-005 71 
19 11 05-007 71 
20 12 04-491 70 
21 13 07-1043 70 
22 14 07-1063 70 
60-69  17.7%   
23 1 04-477 68 
24 2 04-480 66 
25 3 07-1051 65 
26 4 04-473 64 
27 5 04-487 63 
28 6 05-544, 05-565 60, 59 
29 7 05-282 60 
30 8 07-1048 60 
31 9 07-1061 60 
50-59    39.2%   
32 1 05-276 59 
33 2 04-492 58 
34 3 04-485 57 
35 4 05-563 57 
80 
36 5 05-564 57 
37 6 04-489 55 
38 7 05-540 55 
39 8 05-561 55 
40 9 07-1045 55 
41 10 07-1056 55 
42 11 05-546, 05-566 56, 53 
43 12 05-547 54 
44 13 05-570 54 
45 14 07-1050 53 
46 15 05-281 53 
47 16 05-001 52 
48 17 05-004 51 
49 18 06-219 50 
50 19 07-1060 50 
51 20 07-1055  
NI 34.6%   
52 1 04-482, 05-569 NI,NI 
53 2 04-490, 05-568 NI, NI 
54 3 04-474 NI 
55 4 04-475 NI 
56 5 04-478 NI 
57 6 04-481 NI 
58 7 04-483 NI 
59 8 04-484 NI 
60 9 04-486 NI 
61 10 04-493 NI 
62 11 05-002 NI 
63 12 
05-003, 05-277,05-539, 05-
572 NI 
64 13 05-278 NI 
65 14 05-280 NI 
66 15 05-541, 05-573 NI 
67 16 05-542 NI 
68 17 05-562 NI 
69 18 05-574 NI 
70 19 07-1040 NI 
71 20 07-1042 NI 
72 21 07-1044 NI 
73 22 07-1047 NI 
74 23 07-1049 NI 
75 24 07-1065 NI 
76 25 07-1053 NI 
77 26 07-1058 NI 
78 27 07-1069 NI 
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 Appendix B The list of healthy controls and their XCI pattern 
 
Number  Sample 
XCI 
Pattern 
90+ 2.4%   
1 1 03-733 92 
2 2 03-715 90 
3 3 03-745 90 
80-89 5.6%   
4 1 03-698 85 
5F 2 03-772 85 
6 3 03-771 84 
7 4 7462 83 
8 5 03-777 82 
9 6 03-723 80 
10 7 5713 80 
70-79 15.8%   
11 1 03-856 77 
12 2 03-861 77 
13 3 NK-036 77 
14 4 03-826 76 
15 5 03-727 75 
16 6 03-840 75 
17 7 03-858 74 
18 8 03-711 73 
19 9 03-726 73 
20 10 03-738 73 
21 11 03-847 73 
22 12 NK-001 73 
23 13 03-846 72 
24 14 GK-11 72 
25 15 GK-19 71 
26 16 03-708 70 
27 17 03-841 70 
28 18 03-850 70 
29 19 03-712 70 
30 20 03-839 70 
31 21 03-852 70 
32 22 03-862 70 
60-69 31.6%   
33 1 7977 68 
34 2 03-833 67 
35 3 GK-01 67 
36 4 NK-053 67 
37 5 2670 66 
38 6 7688 66 
39 7 GK-22 66 
40 8 NK-018 66 
82 
41 9 03-701 65 
42 10 GK-02 65 
43 11 03-836 64 
44 12 1828 64 
45 13 1883 63 
46 14 2718 63 
47 15 NK-003 63 
48 16 NK-052 63 
49 17 1717 62 
50 18 03-363 62 
51 19 03-366 62 
52 20 03-709 62 
53 21 03-746 62 
54 22 03-778 62 
55 23 03-864 62 
56 24 03-731 61 
57 25 03-813 61 
58 26 03-703 60 
59 27 03-720 60 
60 28 03-728 60 
61 29 03-760 60 
50-59 52.6%   
62 1 03-821 59 
63 2 GK-23 59 
64 3 GK-?? 59 
65 4 03-713 59 
66 5 4396 59 
67 6 GK-05 59 
68 7 NK-015 59 
69 8 03-364 58 
70 9 03-706 58 
71 10 03-717 58 
72 11 03-729 58 
73 12 03-747 58 
74 13 03-768 58 
75 14 03-855 58 
76 15 7127 58 
77 16 03-775 57 
78 17 03-822 57 
79 18 GK-16 57 
80 19 NK-012 57 
81 20 1944 56 
82 21 03-365 56 
83 22 03-705 56 
84 23 03-718 56 
85 24 03-737 56 
86 25 03-740 56 
87 26 03-761 56 
88 27 03-773 56 
89 28 03-780 56 
83 
90 29 03-816 56 
91 30 03-860 56 
92 31 4610 56 
93 32 6096 56 
94 33 GK-08 56 
95 34 NK-039 56 
96 35 03-700 55 
97 36 03-708 55 
98 37 03-735 55 
99 38 03-769 55 
100 39 03-830 55 
101 40 2290 54 
102 41 03-722 54 
103 42 03-744 54 
104 43 03-817 54 
105 44 NK-040 54 
106 45 7264 53 
107 46 03-730 53 
108 47 03-734 53 
109 48 03-762 53 
110 49 03-814 53 
111 50 03-832 53 
112 51 8268 53 
113 52 GK-24 53 
114 53 03-704 52 
115 54 03-714 52 
116 55 03-725 52 
117 56 03-732 52 
118 57 03-741 52 
119 58 03-776 52 
120 59 03-823 52 
121 60 03-767 51 
122 61 03-820 51 
123 62 03-702 50 
124 63 03- 50 
NI 22.5%   
125 1 03-699 NI 
126 2 03-707 NI 
127 3 03-710 NI 
128 4 03-719 NI 
129 5 03-721 NI 
130 6 03-724 NI 
131 7 03-743 NI 
132 8 03-763 NI 
133 9 03-764 NI 
134 10 03-765 NI 
135 11 03-766 NI 
136 12 03-770 NI 
137 13 03-774 NI 
138 14 03-779 NI 
84 
139 15 03-781 NI 
140 16 03-782 NI 
141 17 03-783 NI 
142 18 03-815 NI 
143 19 03-818 NI 
144 20 03-819 NI 
145 21 03-824 NI 
146 22 03-825 NI 
147 23 03-827 NI 
148 24 03-828 NI 
149 25 03-835 NI 
150 26 03-837 NI 
151 27 03-838 NI 
152 28 03-842 NI 
153 29 03-843 NI 
154 30 03-844 NI 
155 31 03-845 NI 
156 32 03-848 NI 
157 33 03-849 NI 
158 34 03-851 NI 
159 35 03-853 NI 
160 36 03-854 NI 
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 Appendix C The PAGE figures of XCI patterns of Sjogren Syndrome patients 
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